var title_f8_28_8640="Percutaneous transluminal angioplasty of iliac stenosis";
var content_f8_28_8640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Percutaneous transluminal angioplasty of iliac stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiography in a patient with rest pain shows an eccentric, 90 percent stenosis of the left common iliac artery (left image, arrow). The stenosis of the diseased segment is eliminated by angioplasty and stenting (right image).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Julie Zaetta, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8640=[""].join("\n");
var outline_f8_28_8640=null;
var title_f8_28_8641="Strep throat PI";
var content_f8_28_8641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Strep throat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Strep throat can make the roof of your mouth turn red and your tonsils white. It can also make your uvula swell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8641=[""].join("\n");
var outline_f8_28_8641=null;
var title_f8_28_8642="GERD PI";
var content_f8_28_8642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gastroesophageal reflux disease (GERD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 547px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When we eat, food is carried from the mouth through the esophagus, a tube-like structure that is approximately 10 inches long and 1 inch wide in adults. At the lower end of the esophagus, where it joins the stomach, there is a circular ring of muscle that relaxes and opens when food reaches that point, called the lower esophageal sphincter (LES). This allows food to enter the stomach and then closes to prevent the back-up of food and acid into the esophagus. Reflux can occur if the LES is weak or stays relaxed too long.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8642=[""].join("\n");
var outline_f8_28_8642=null;
var title_f8_28_8643="Naftifine: Drug information";
var content_f8_28_8643=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naftifine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30931?source=see_link\">",
"    see \"Naftifine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea corporis, tinea cruris, tinea pedis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Apply once daily to affected area and surrounding skin for up to 2 weeks (1%) or up to 4 weeks (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Apply twice daily (morning and evening) to affected area and surrounding skin for up to 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naftin&reg;: 1% (30 g [DSC], 60 g, 90 g); 2% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naftin&reg;: 1% (40 g, 60 g, 90 g) [contains ethanol 52%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14181999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Wash hands before and after use. Apply to clean, dry skin. Avoid occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of tinea cruris (jock itch), tinea corporis (ringworm), and tinea pedis (athlete's foot)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Burning/stinging (5% to 6%), erythema (&le;2%), pruritus (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Dryness (3%), irritation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, blisters, burning, crusting, dizziness, headache, inflammation, leukopenia, maceration, rash, serous drainage, skin tenderness, swelling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naftifine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; not intended for oral, ophthalmic, or vaginal use. Avoid use of occlusive dressings and contact with eyes, nose, mouth, or mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5204542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies following oral administration. Naftifine is absorbed systemically (4% to 6%) following topical administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5204543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Naftin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 g): $341.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (45 g): $341.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Naftin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 g): $341.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14182001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Culture and KOH exam; re-evaluate if no improvement after 4 weeks of therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A Mei (TW);",
"     </li>",
"     <li>",
"      Chizocin (TW);",
"     </li>",
"     <li>",
"      Exoderil (AE, AT, BG, BH, CR, CY, CZ, DE, EE, EG, GR, GT, HK, HN, ID, IL, IQ, IR, JO, KP, KW, LB, LY, MY, NI, OM, PA, PK, PL, QA, RU, SA, SV, SY, TR, TW, YE);",
"     </li>",
"     <li>",
"      Fang Di (CL);",
"     </li>",
"     <li>",
"      Fetimin (HR);",
"     </li>",
"     <li>",
"      Micosona (ES);",
"     </li>",
"     <li>",
"      Suadian (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic, broad-spectrum antifungal agent in the allylamine class; appears to have both fungistatic and fungicidal activity. Exhibits antifungal activity by selectively inhibiting the enzyme squalene epoxidase in a dose-dependent manner which results in a reduced synthesis of ergosterol, the primary sterol within the fungal membrane, and increased squalene in cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic: Cream: 6%; Gel: 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (as unchanged drug and/or metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Parish LC, Parish JL, Routh HB, et al, \"A Double-Blind, Randomized, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Naftifine 2% Cream in Tinea cruris,\"",
"      <i>",
"       J Drugs Dermatol",
"      </i>",
"      , 2011, 20(10):1142-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8643/abstract-text/21968664/pubmed\" id=\"21968664\" target=\"_blank\">",
"        21968664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parish LC, Parish JL, Routh HB, et al, \"A Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Naftifine 2% Cream in the Treatment of Tinea pedis,\"",
"      <i>",
"       J Drugs Dermatol",
"      </i>",
"      , 2011, 10(11):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8643/abstract-text/22052309/pubmed\" id=\"22052309\" target=\"_blank\">",
"        22052309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9675 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8643=[""].join("\n");
var outline_f8_28_8643=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199234\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199249\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199235\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199236\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199223\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199211\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14181999\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199224\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199247\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199227\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199215\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299736\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199219\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5204542\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5204543\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199228\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182001\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199229\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199214\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199226\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9675|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30931?source=related_link\">",
"      Naftifine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_28_8644="Doxycycline hyclate periodontal extended-release liquid: Patient drug information";
var content_f8_28_8644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxycycline hyclate periodontal extended-release liquid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/18/2340?source=see_link\">",
"     see \"Doxycycline hyclate periodontal extended-release liquid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atridox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atridox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the tissue around the teeth (periodontitis). It is used with scaling and root planing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxycycline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696737",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not brush or floss near the area for 7 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew hard, crusty, or sticky foods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain where it was placed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad pain, swelling, or bleeding where treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11942 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8644=[""].join("\n");
var outline_f8_28_8644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854887\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015506\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015505\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015510\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015511\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015513\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015508\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015509\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015514\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015515\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/18/2340?source=related_link\">",
"      Doxycycline hyclate periodontal extended-release liquid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_28_8645="Ichthyosis vulgaris 4";
var content_f8_28_8645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ichthyosis vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 397px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGNAVwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDoLSJSVJJI7Gr0SJtIOWJ5wOCKggXdg7iQeCMdQP5GreGZkGfp2OK8pnoMaEJ5XgZ698UOUbJO0sB8rD0pXIBRyeGA6nn8arXEoXOF69QfSpAimdQRjr296qltzEbSBjPSnEsxAY9fepYYcsPmxjt3PtVpCYkQwoJwoPTJPAq9boAA0mdnUU23jBbc24KO3ocdMfSppMkEI3AxgY4xVpWJeoTytMWDEBRwNh6elRAKCdpfrwPX2pzfOecDGSCP1qJCGOAc9mx2NJgkPxyckZxUhUlAPTkAGi3G8jBwVPTtiptnIYcZIJ/+tUjIthJxz83J70yRWYtjGM4xjpVtFVuSdpB7GmkJgk565YUhlIqRuzk8dhUEkbFOD6c1oyQj52ZTgr1B4PNQiNVzlgOByaVx2KTRfMTk47ccGoDbiIAsQe5xV5wu4pkrt6HrzTGUggEDcT3/AFouNFRIT91umN30J7U5bbIBxktxyenvVryydzY69KmCkDAAC/19KXMVYpJbAhTgLzwc9aHgPl4XJIPOTjA9a0EQs+Cucc46d+KSSM8Ieg9fSi47mZMgL5C4A4wOlReRyWVhuIwQOo+taTx7UGVyBjpUbQhpSxXoN2fU00xlD7Ozdixx+X/16Z5B39ATjgA1dddgbbliR0z1phTBUyYPJ6H0p3AqJHhM5O0ce9SGMjCuRnPYdKsKozjOV6r2P5UhjYrllGM5PPSldiuV1jwoAbd7HvT8MgHygY9O5qd1JBOMgDJYDqKYFf59xXnhQO1AEDR88HAxnd3NLtJU9NwzwDgEVLIrhSuCzOcj6dhUSgL5mM7uV9vrTAgOcNjJxxx1qNjmRsEnK8A/zNSTALGrBzwSceo9KpylzKArBuCwJ4BqkMTe3APQg4PrTQ+0nOQeoAqJ5AicYIzjOckGotw4+YA56gU7XFctiQq+C/Tow+lRbigIVhkHIDHpUO8qvzE7gOR0zTZHLOoBHFLlHckeTdCxJwM9QKqtKcAHBLHr0FJNKwUEZ3HLD0B9DVOeRpCrI2wLw2ejE0NCuWZJPMyC2cjbgdzUbgxkIVVnK59qqw3IkV4ztCr0xySKnJDfLjIVcY6ZpAVpE3bN75ByPvHANRkDOVfaG5wx5NWJAV5Vxt53ccACoPL80l8MSTzmpaEeqWo68uCDjGetXM9MNg/SoI0CqGwSD6dRTpCPLBLY9x2oJIppcKM5AY5AA61RkfzG2jIUnHB6cVNOw+TcCe+c45qG2jDGVncMVOFIPJ98elXGNxNixxnK5IJz07GrsEXzFWBODww7/jTLe3IlMkiZG3buOetW7aJQ+MDK8+zH2rSwgwEVVTBXqARzj0omVT8wHbA29x61L/DvVh5Z7ioW3B2IAB6fewMUWuwISFaTbnrzuzz9MVJGCsi7yChyGA45xwP/AK9I7CQxjaFJypOMHipY/LVgjSbYzt+Yjn8f1ptW2JTuOhiYKGxnJxnOAwqYoFK7gzZ6gDt9aebfau0j5T83lDggjuPSpUiCO4zjdjgnkjFZtDIlCcAswbO0lu/amsiryY8Eg4QH+VTAAR7VOV5AIHRhQFHmZwBlsE54HHT86hoEVWymcY65BJyBUJiVRgoo/wDr1dKMCADtKDkZyD7g1Cw3RspO7jBA6j3qS0jJvbed22xPhc7QB16dfpVUR3kTqjEtk5JYdPxrbkK5yWHBxx/LNRnJBDkEA8ik5FogAOSScLgHjrUqngdDjrUQwGweh4/CptpOcHBAqBseqZyDgBjjcexHb/PpUpiwCWBctx15x7UwbVACnJxn2B7U9gB9xeAMgen1qkQyHyVAIDttU4APbpgVFKuFXbkqDxnsPWpzlycYC88+9QkYUgNkDgAmmBVdSCCo6DIz/Wo5IwP4jkAE9+BUzn5SxbC9AR2oRcFVUAyHgc07juRFQ0ZIXnGeeAM9qUJ6HqO3Tp2qQfMQTkAEgZ649aa8Yyy5O4DamPcfzp3EMcYk+Yjbj7o9KiJKpjj5j35FShAzY5BIwB6ge9KcnA+X5id3sPWgZWZlYBg2RnoDzjtj9arlSW5x8p6r3/zxVuUxjLbcJyN3cYH86rtHvZ+H3cE84/GmhlWQbeQnLE5DHge1VGVXz/eQ8jPT/PWrswyr7flGRg8HHr+eKrMEOUBBRmxgc8gZ5PYVSQ7mfKP3bBm+cDrjgHj9aoyTqCvI9VweM1oSjlTGByMsR0Jx1rPvbcuoaNguwBhjAGO2a0RDHiYBdrvz6H+Omsw+XHCk/wB48e/1rJiuVilbzXSPABJc425rQZ/kYGVgxIYYPI7EGqWuqFcJ5M7sOzA/MQegFZrv84UvjqVDdOvT61cupiF64OcjjnpxXMahd+UEbcQVddoZvfPSspaOxW5NDfCLU/LZwFIOOep9K6SFlMaHcD8uCRn8689aXz/FdiyspVt3f0ByK75FWGMHLElcAdf8n2qZR5bPuCJZeScDcwABGenvUDnDHcob0JOOKmXBWNgBuxlTng0khjYjjGODxUNDPVdoC5b04wKYyhsZwq/Tg1MeGJUcY5HTFKYycY2jB45qjNGXcE+fEq4Dn7pJ7epq7DCiRhEK4Y/e74qG/URzh27J24B5pLaUG4YEtuJwzdRjFdEPhJerNONFPyAkDHGCf19atxxEANnIcZIVs9O1R6cDJHI4QsyYVSeccfrWjHbrw2Tg5JHTLe1O1w2Mq7iyqnaQAein9Kw7u8xNsHzLzuA5/P8ASui1eVIbWRt+UXBPqT2wPc1x9mplZ5Gdcncxz1B6Y/Hj8qlPlHa5r2vIDYClMBTuxkdf6GtO2jC4ChPnOfmPIwM/rzVK2Tq6I7soEmwx5DZHQemOT9K0IQZYY5xtd1UhSSO3OB79jUN3Faw5AjRyPHuG07vdD6kf3e3WpEVlG18Ng7Q2c5/znipYVTPyAlSodQjAg4+9g9zyeD6ULAdjKDuIVdpBxuXPTHtSAh2ZVtq7gy5ZgcbSOP8AJpImctkphxngn7wx/OpywLFsEE5fpweOQCOlQ/Kcg7pQTvIYAMR3K+4qGURSqmRkkKRgk85XPX6imSE9GOWTDZ75HpUjgtgqwVyNxAGNw9frVduVQMQpHyEHnJxxUMaEkHmD92qBhzjoDVdwWYDfjOR1qVQRgbAAGwcnGD2/D1pp2sdpGG7r0IP+e1JlohwOVzhh19qegwTjLDGcmm7Rjdg7gf8A9dOjA8stnAH5VKAmUFkDAnjkY65qYEKGODtOBgng1BAeCx3YK9DxmrKAlCSBjhvXHFNEsjcBI1QAnGMenWqtxtLncMkH15//AF1ZcbgCCQx5JPeq8rgKM4GeoqhFaTA3Nj5VBJHoPSgjcVA4ReTzyTUh+fPQkYOTwPpmmlBgcYzwxzyfXFNDBRlCx3bnOV9s00DMg6lgSABwMen1NOYOsWCQ5AxtHT2HrRtVSACMqwznhR6dKqwEbIwCjgMcDdnqfp7VHIpzhgSm4gAd+9SFo1Y7NxZl3ZAxnPT3AoXuZOiKAWBFFhkR3bxIc9mAPLHPHNQSDAxktjKg9uT3/EVZbYSVaUknarMowev8qruBlhIcbPnOWI6dh7mqUQuUpF+Y4BO0kEE9ff8ApVWUHDRLhVG3GO4xzmtDaN4U4Xed4XpwR39qryx7kDE4LfO5x8zHPA9h0qkhGdKySBkI+4Sis3cDqRVK7UKgL8Fd2Pm5Y47DsK1btN7JGq7mkIYN7tycegwKzJZBI/mRvDJk5BXlT6DP17UMDm/EFo8kMpgRVuY1Ei7jkDoSDjrUWkahHdWxYZDn5QhJZlPqT6+1ajcRlC4DsxwV6gjljn8uK5C8/wCJRrTTbGWyvSN2CT5cvvz/ABdef6UU3uluKSNu/uMhd3yhsqyn1Hqe2a4/X51V9ifKwP4Gtm/uAMurHa5HQ4KfQVx+tMXlQZHznBw2cn1PpV0o80rseyNPweWn8RW7qMiEMWPUA8/MK9GlwrAo/X73zYPNcD4CiEepzFeSkYH/AAInHH5V3LkIwHzb+p45NOutSISvqSpIUYYydoI29jTyjtzu3e4PWqjuArKSo2+vUZ71XuAgcblYkgHliMe1ctzS57mI+m7BDccdzUkcJL4I4HBB61LGqg/MCRyTt96s2yZlU44IJH4VVjMztZtgbFinJCn24rm9Pm/0hwcDPA56V214v7mRJFUqwIIPeuCtMQ3MsLcvH8rYHJ9DWsdrDR2uihlUn5WGC3UZrURlj/gDHGMN1GawNMZSjI53OBlTxniq+val9lsCY3xPMPLjBP3QerfWr5tBON2Zeu3v2/UViGTbRvjAON7jvn0p9mI7e38wkg52kgg4B6cdzWZZYhiR8qRkh8clSOAcfTNbGm25e2ERTeyqwJiUsz4OVAx3H61k9S7WNWxgaYQqRGJEZ4Qc4IPHXHsMVZRxI0SRhXDx+ZHGwwc5wQG6H6fnS2jxr5l0weFIyJJGIyyjoUYdQTnP41ejWIzsqzxuJV2tApABYc5U9mA7VSjczbIrePzWWNNk0E2QqO4V4mHJGOuR+tRNKhkcNI6soC7d2PmPQ/pUhWFo5WecLHEdzFRgxsfulu/PqKe74lEcrHlEZHK5Dg8jPpyabiFyuzhJUw+xy+4Y4DcYOffIqKQgOUhVd/LoN4GRg9Oxp8mBBsMTLsGPmyOnP1z/ADqtOuPnjP7uEh4jxlMnH4+9ZtFIaj4MZeMxKQQUJxu9x9KhnYPDIkoO0KNzLztJ5H8qmJLSEMwYDhl6Hp1GfXimttdOsbMuFHmgq3B6ED26Vm0UQylVYMjtuOQMjIBx0NV5N2AwfHRhxyDjmpVMbO5G4Fm3Kp6gY5/L1pr4MTMHGM9++OCamxQwklSoOCRzn0pMkchQG6Z64P070iqCgBIweKQMTECpCswwpP8AWkBZjIBVS3U4OeRjFWkU4ZidrZJ49vaqkW1WxkFVHC9+OtX4QBGRuxj1OcH/APVTRLK8wzPgg4PO0HoaqGPcgYncM+nBq0z7JhzwGznPA9KhKqgKjaAq9CfemkAxY9sZCsWYfPtB4FIuGc7mBION3oO+P6U8MHjJUhVU4PoG/wAOKj3llyTkFtuQvfPNWkIWTBTlASckp0P4mo43O0gKAoTIXH4D8akPl+SF+VgTldxySfX2qMnyZGKlCI1LF2Pt1qkhEaxusb73BlIxuOAoHZc0xzsJadjy/BbPy+nHpSxlGiwN2wD5QB9046EVBOxLKVVRGCCzM3zEj+EA9RxWiiO4/KKm4FdwUY3NtHB4JHeoJGCxMQdpY5Xdk4A5NMn2CQs+6Tc2zb369PYVUE5OAoaTcxYAHO485OfQDt3quUVyZ5cKHjVsFf3YLZMmT1Pp3qB33BxuxHG3zHopPYfn2qrLeupErbmYBtu4bCxyAGAqtOyLIbUeYbgbTlfugng498Y5NLlKLF40Lq0skgjiG752bAfIwc+gHSsq+2eSW48sxRtsRs4jP3V46Zx19qbf30c3iOysiyyobZ5hCV+SIBipfd/EeMFT7GuK1ue41GS9udMMyXMcaQqki+VLFhuI2XoSpBx3INLluFzqbsmW3uPLHCMGcp8hxkYUH69a5rxDF9rsJIGSNySACH+VWxxirl3qw/tiezdYbYrtuFIOdoCgMo55bO7g84qpqH+q/wBYDDEm1FD8ncc7iPXNRZxkmUtTl5Lxvs4huGImQYY5yCB0rJJ8y7aQ4wF28etaGqxo0zCPgNkkg96r2dsJJYoGYgOdrMOwPU13xSS5jnnLTk6nW+Comjt3kdBgksN1dBLkHDSAgnAzwQfTNVNPt0hsYlQkLHgLjksfersiZ4ZguckYHQ1ySfM7lR00KjBggVQF5wQTyRnjmpVjVsksjc9S2M01Sd2ScseAD6+9RmZ1Jwcg8/drnku5aPolAT0XazHbjsQP5GrMa9NhKDHJHUGhWxgFs5Gcjp7U5ThVzz1zjtWliCK5B8nYRyBnHc++a4fWoRbagLlRw48tyD78H+ld9Jjym2qD3Ga57xFardW7RkAA8ccY7/zprQpGZY3Cs2wvtdTw2eay9UuJLq/BbDCM7QQeD7c1T0+5eGaS2lI82PjOeWHYio72dbeGV5NzCNCxTIyT2x7k1Vihbu+EEFwbZWMyBUzjKozHClj643flWx4W0q5kaRPtknnSQsqlGKtESPmfOeCexHPNYGhSXX2UXSymUzmNGRF3EO2SS3t2z0rs9CSDTtJvJ7Vvtpnm2Qsp5iI4wR9SSc+greMEZykdLpcaTWbSqTcTlWh+ceX5ygYZcnuMdT6VbMUbbVSIJIvzInRwQuCQ/c4x1qlBOkqobqORyp8qZ4yCDxkOo9fWrCXQaWYR7SEjjwHBXzVP8ee3Tp3pWXQjUmjby5/KKyJdquYnHzMUPUse4B6Zqq8G6FVnDLAS+WGcqQcbcn19KtiS4ZnjjOx02tHKcMmf4SP84pOGkfdMFDr+8JPAPfI9/WiwbGbKZliJbIlLAkk4yRnB/lVabcWkbyxGpbMgYZAY9CPStKcoCsU2yFFwp2ruznsfYj0qCZCiR/6vJUqAsmVcZ4465rOUWUmZruJY0Uxsxk+UAHlWA+7/AFFV5X2LJhg4UB45Cdx65OfYdMVPlZEUJIsm4fIV4Y4HT6jBqJ40RonZidoJcH7rAjBx7Vk4miYwHcQ4BXjO3IwD0I/HOagkASMomEXYJEz1pyP5IcQmRU2NGrFAcqeRn0IqJphLGmAysvyKTwAf/r9qz5SkOD5Qr8u7dgDryccflUbbURdw6E5zwQOgoAKZwQ4AxnGAvappYxvDBhkHjnPNLlGSQ5IJIVkcZI9qtcLAAxwrdSPTNVlRPNzg4ILEA/pUrcKoX5QBnbnp7H60kiWM4JQHGT0X27GoJPmQ4OMkH1J9qk8wGIMeCcKMDrTHfbMvl8Dd90nnGOo9qpIQ3HzYCkKRu29PoT7cUIyMhkX5sjaewTHakLsHITHAydx9+1Qysu5FaRjIpyAPbqTWiQgbAnLjghfQhiMdqahLR4G0E8hG5Ppz/wDXpkE0aLn7rZ+UFuWA54pk0sUkx2lpMHJIGOo6Ee1aRQMcsmGImkYSMG3YGDjH9elVppNkYJfmOPIB4IHc/WiSQkklgJFBZ8cj65/pVOaVyzRgFjsyxDcn6e3rWiRIy6k2xsoXy0ijLbkfkDtn35qvKHIbzWKsVKO542g8hR9cdKJC2ZCJtzOSD8vQk8Lj+ZqlNtjlUErtBwzdSxweQO/NCQyP7Qf3Vxhd5EoUOdrhxwFAPQ5z0qg85jlXyQsU0QFuFC5PmsTu3OOSR7cUksqSoshjSKRceWs4O5WPbHdsjOKrTTmPCiaJVj/dqXPViMHBHO4nH0FS0MztRkdNNvhatJBKIXsUuwCzsQxwuB0G7A3HpnvXNXF8dKspLS7Msly9uBdzzN5wSXqFUdGYE53ZOPXit+WY/bAV8uSKNkhllH35Ni/cGemXOePQVxmsW6z3xkuZSIlXZtRf7rEFQO7E5wfeqpNbMTT3IbMLaKNXhuzOwJQiWPcWmI5yDxwGzk966ETxPapFB5jKOXd/vkkYGQfXGfpXKSHbKoWPhUwiHAwvYnHBP61pWDhLVPMUiTJAUtgAnjnuRjn8a0nC61HB3H6gNwOxcncBuXhdvqB9aseF7d5rt5E2ny1AAbvmqEs3lys0T7lXOD/fH0q94VkCap93cGjwFzjJ4pv+GyKqtNM7q3iUIq4O7byqkDBphQICSFZgAAxOMjP86lSWJER1YFfugLzjjv8ASomYEqS/IPaucZXclnfhmycDP9aNwRiqhCAepHWljYJlgNxBwewPvSE7QAXA44G2sWi0fSQHHQc5APpipFiUgspOenJ+7+FTRrlVcnknse1MEbIQHBBfOTn39KtEEM+3jDEjGcVl30ZBI43YyTn9a1nPXO3BGBWZqGCrt8u/bwDn8qGUjhtXtU/tNLgDDKpGAcA57Gqd9I62hdGyFIZwFBPlgfMPf1/CtPUfmnlB4AHIPvVdY13KQ23JwrAfd46k0xo56K4uLTTYpbWHZFE4hgaN8lgckMR3yOfauz0MSxQXriQQs+yRoFGdkv8AFz3HSs+zgjt5ZfKxtnCiRATsyoI/XPatiAiCJlHmKjYRducgEfzGKtz7BY2raYTQbzhQc72QEZOMHHowHOPerccqiUW8h3qoRShPIzkgg+ntWSsh812dQ53bHcEHPYEjPBx3qaJyFWMlVkjHlqVBH3R0OeOnSpTJsaccxkthmRGC43oxIOwnGAfwq5CW3IqYk4JycAsM/wAvasiK7WOVQrBRguVYZxxyAO4+lTWsyBZV3lw4Yq4BwDjqw9+laJ3IaJ5iHhcFguEyrsvDAHjkc+1V5kw4EdvmRdkpJ4w44ZVz1GOaseYfNjkkVFeIOu5HGx0HIDD0FU2uQ8aSvtYAsCWyGGejBf1pu2wIpTrGFLwxR7FBbK/Lu6/KR696qSyMAhd1RMiVXJIyCvIP179OavlSZGVw8bfwknOGzw4PY8Vn3Sb2WPbC8kxEv7uTackEHI9ODmocSkyGV/s0qCYuhz+8TOdpP8XocEimxyj7U0Un+sDBSNuA3/18GmwxbbdLdRlM7pVj/hxnkZ9eD+FRwv56Om4FQ+Bkc5GME/1rNxLTLiEMrCEDcV2nJ68/zFSRZMHdSOoDckDvUMI3hum/zCyHG0MOmR+tWY3BlXayBwcn3+h9ajlC5NGdxDRnJxuGDgZodMHzFdV2Yyc9P8c5qOIFdrZVEztdc5ZW96RnG4hwcJ8pH8/50WERXOASoDB1K8H8847cVDKg3FgzMGO8g8MeeOfrVoFmB8s46fMCSSM9xVeWPnLPGSmQDj5RVJCKrMPMjSZo1mIDMM5xnoAaidiI5PmO0nucMUz/ADNWJGk27yMnk5PZfb3qrJuacMUQZAyT79BWsUA2cshyhZkBHy8DcvpntUM9yPmjj+QkMS4PKjsMevpRKxRiHKs2eWzkH3+tVZ5GCbTGADh3ZnxkjoM+3Bq0hEtw4UKGcHzSzqq8Axno2O5z2rPaZgrIJEaXaNzbOYxjpk+vpUUlyI7gtvdnyNzIvMnH3hVGa6bkxsE58wsTjZtHJPr35o0AsTXIEQEhIhQnjfjJ77j6VRkuLgxS3McUcQJSNWPChSeVHufX0qCa7jeR0RmkBYgyBQCoHrnoOuCOtUbmRmmkkmitS27cpcZO7B24X0UDknvUsZPcXkCb2hliLo/WYZQADquf5+9U3lKCGQSyJGpPyrGN0hI+4pIyvAyWqndXz2kF3KkcjCJhJ5srY858/MQMfw/wj6VDcNJFKYEIl+ctdSyNlmPX5iuRwvGBz0qXsAXNzIDEIiySIoUKwACqVPMhHCDkHJOTxWHciNls5Y0ZLZVZbYyFvmB+/MA3IB/hz6Vau3m8w+WqC2VTKQV3AuQMBgOpJxhe2KoajLNNtmmeSdyNskkoGScDChRwAM5x61cEMyZFV/lBKFCdqsePp7euaaJfny7OcjBPcii62yMChwgyOev41AWHGGP1FbWKvYmkk3AZ7DH4CtHTZPK1MOoJOMDacE8dqxngZ/mznmrtuxjmjZGIZCCMDPNVbRmM5KTR6LbSBrf5WUrjoD0OKEhId5eA8mNwJyAR3rOs5cO24q/AYA+p6ir0cu6UjjywQT2O72riT01KJigLZxtAOcjPWmEkfz6VIxfeMn535+aoyNoUAhuOctjFKWhSPpmMEMGO0cYVew+tTfJgncSuRkenvmiLLsZVbzFPXHGPwp1ygVDjIEg/T2qrEXM+Zl+XaAD1Oe4rFvbgKh5BJyOP51q3m0RgEq+336Vh37LslfcBIRzuPBHpUvsWjlLuUnUnBO/5c59aehUqV3EBDnBPH4VmXzrDq0YU48xGGCeR34qdZSFB3NtPBGOn1q2tBmjG4HyrnaeODjj0x/WrtvK0alTllBIJJw2P8eayYpNpOSgYjIz0P4VL54jUsSQinH+6ayaKNQzx+acOUYgg5HIXHHPSpEujPAybyV27c7vusuCAR3GDwayjIoG5woyRyTw34U1ZleMtn7g2sG4Iz0z7ccfSqCxtR3TPLFFKwhO3EUir9xs8r+NXhPDGiysds7udzID94dQQOnAzisFZpFTegHlOpdl3AoPXB7fSpYb452kzDJPy98YGfYiqTtoS0bMd4gudjMwG4ssgBIBI4JHdafJeZWRvLMxVQWjQgF1PHB7ev4Vgm5kDMfMBeJgwGcEpj07/AP16kt7gCSQA+YmVZQw2svcf1yKpMlxNrEhghjUyeXHIsgJOS2VPzDPXGelVZLdGhhjY+YZNqeY+EZGLcc/U9KmtTJL50e5lZQJNwBKsO4P5Dp6U6ZfPiljliDo6ggOdqyDOVwemc1bRCZDOjW0TQ75S4zG0RAYqzfxA/wAI9veqsqq8jsEYZADIpwCR1K/gOtXjHvjEm+XMqDO8FiCDxk9jiomjSQrFLJljjoMkMDzg+lRLUpMasbsiuoViq5Ug8HrUZB2bvLEcbjcVU5YEenfrV7AEknnEKSMtGvGfb2z61DMgEJkCA4G8LnLL9COtRYdxd6KcAZcHftI4PGMk+9RsSxRVVfMkJ+QAfNgc/pUmRDCWUTbNm7eBklCOmPUVA4UGMqhVo87XHByRyfr7elSBCspXzJYnJjx8gI7dOPxomaJMhdzzhSEXd9044zn/ADzTXiCDaE2CNTsUnqcf45FQSszBgGDEKAPMPQ+1UmOw3ciyK20FxhSmeD/nFQIwkRkjjLvtZiC2Ax7rz2pWfEZdwFUNgn8MCqbSr8rKwfk4UfdLf0q4sVh0qhF/6ZoMEYyQc4/TNUriRmcBFDEnDbhnB7D8afJK2IcvIOFk3Z6buob/ADxVW9YTRoZIxI0rjCk5IA5BA/rVpiMudxNLIySGcxysgJwFi28E/wC0RnpVCafyWm2xqhwqBEBYv8wAGOyjJJ9c1oTGTbMhcyKseXMY5aTOcAnjkbQc1nzIXZLiQpDCPnIBy23rtz7kc0AU764tre7mDzRxKCs08hHUD5VBPQLxwOTmsOe9jtElcRLiZtgfBeSQk84PQjkfyq88f2sQWyRRxwSKWaB3ysLnJ+Y9ccjisLzZnVLpZVHmqY0gAw2M4KqCOisCTUWvsNFxpnW68tnGYmYMCD0yOOuB/wDqqn9pYLaqiHz5C0iY4285357gjPTvxWZJIz+TFbbHVlA2ct8q9MdycDp2qpdXHm27rljGVGWb5iFz0B9Mjp9auMB2NKW43KIxMRsJ2jeIVViTkAHo3Oc9az7m5BVj1iZdkaD+EA8ZP15PrVaSVGjyUT51/hGT15Y56E4qAbpn5BC+9apA3YQkyOqH7p74qwkPlAAHinxxhORTj0JzWiRhOdwb0JpUYK4L9ARkevNN7dARUVx/q0xuzvHSh7GcPiR1tnII4ztXITIxjOCe3PetqLctuCMAnkFuSD6Vz+kyOttErSN5bA9Tj5vUdsHNb1qrKN2FUZyFB5I6Zrgt7zsdLLofzFJAyzcEg5xVC40xbyTzGvpYSBt2owUH3wa0IFQoxztZsdsZ7VHdWEE0xe4Y+Z0IEhGPaqaGj6it1VkTpk8YHHNNmPlqy7QRnABPb2qzAoVmB+Vgc7T0AIqtK6+WwDEPjJGcAf40GZj3zRBmHGBnGT/Oub1OeNlfyWVj0cdcVs6m8sbI0KqWA53DqK4DWpWVZlhjkFwHVvlH3jnpU2RskYviFyur2DjOfMIOfQiplfYGG8EnpjsKpeMJWjksJWfaVnXf754wfzqwpyWQAgrk7u30+tataC6lpLhcDJO4cYI7/WpFud5YuzDHbpu9D9aoHLOectj5sHFOBIbdxnOAtZtFJl9ZW2nGCrDAOenocVKjhJNpI3kFdqjG5f6gVQLbWLK2QR2qeA/PiMhckHk9P8KVh3LaPhVbPIBxxw2f4TVmPLQSgElVkJMZJ+Qkdj6dap20Jl+TBLNkDI++M1oLCWBkjJYqCo2dSvYkd+9OwmySJUPlgfNEoIGWyQMDkd+o/StS2hkTcyucgrOHADn6j1Xg1WtYALuLLxbZY2xO3EajBGWPUHt061ZPkwJB5kDFF2gqjenJX2XH86ollyPaf3s0rxP8wBI++nXA9fpU4kQQhMOspUJkthVJHTHb2qlC800iyLtUMOCq42n2/AUxZkbL5bPBXD5BYdWJ9afNYnlLEjzpujDMWZsKd2d49MfpUVvskDNGGwSG25GAenPt/Oq42iWUK/zMfNYg4DcdhUsQJy6hCqkbWLYY9MsPp/jUOXQdrF0qAEZWXd0Ow846YPvSSZERCt5gBGBjPrxzSDakTOSqAMcsmeB64PU08NvUgMjYAK7Thj65H8ql9wIW+9lFJ3gkDPp26/rULplSitIFAXG0ElSSM4PrxT3cb0KbYmVeRsy3pj8elRyvtnlDDMgA4U7c8jn8KQyC4+eSbylcNIQeDnAHXHucVnXDgw/KdrABlC8bRnqfcirtyTA07tufZg7Qck98g/jVOSLKsu3/AFOBtB68ZI/EUikilJIizBVEn3gvt+NVHmEiNlgx64X7vWrcsG5mDnq4cEHBOc4A9qoMNhQv8nOW6KEXqSfxpp2KsRSHy98rjMrFQB6LyPpVWV3QqynEjArlcfTA9D2qZCGQBmLDIJJHU9QfpVOcqV3/AC4LcE9SPWtEyGio858uASultgcnJPzZ6Be52jjPvUFyziXKrb5RHdVkJyOPl3euO9WZ08uQsrZdeQuMbR15H6VQeRUJhjaQbVLELjK7umD65zQ2KxVkZWmgSEtI8zK7yAclVwAW9M+noKwL8CRQiMRsY7El4IXnkD+HJ966CcsIpsKzQRYdyjYkkI5KZ7DoT3xmue1yN5fNjuvIuEeVZUSDKlB0VS3tnrz1/IFYw7spDnlXQkFZIgFY7hk4P14/CsyWH5z5Cs0bElcfxAdavagF+ctJvbzGyiL8gPcKPQE496zZtuWCOeB0UY9P0/wrpiilohiKkj4B8sdh3q/DGI0+9uJqlEYV+bncPWrsbeagYrj61ojCo2POSab70u7r6000zATvmkdimxl6hhil70yfH7sHGN69Rmk9iofEjptFU+WPJCgkA7i+QQT2zXRQyxrIq5Yu4IVegwOozWFpbRm3jYBlCqRnqW963dO3yIshj8uQN9wkZA9q4teZnQzUjQFC3XCnB7CpTAJMHyGdsAMQe9SRH5+VBzwwzyR7VMtuOrozk8hlOARVgfRip5QBXGQACGOc8/0qC+dDwGz0wOwrQWPIiGV+br6ketULtAvRVUE55PNJkROb1MBkZTkAc/8A1q5y9bGXAVSDn/8AVXS6ggkYfe+QYZx1P1rl9RYlSu0EjJ4PH/66yN0edfEuYHRZ5IyuUaN852n74/OtRSNzgElj2Y45rL+IEYk8PXqja+1Cwz145wPyqvp+oR3NpaypLv8ANiR8+5HP0rWzsS3qbZUAlcd+nvTlAYrhsDHBx0qJFMm3c49c1bjQBTypXHGTUMoRYwVGBkk9B0NSoijcT2BUhTjOB0NNXJYKG5GOnUe9WUVeucBhk49aVx2LdusmQkLNuCbuDxk5OatRCNlkWSRCVSMEgYK++fTmqduoHluw3Mo5IPOR/iKnjy/ybg/y4G7+IHsfelzaDsX4W3PEHADEMHB4z6cdPfNTLi4ETKu7LFyoIz6E5qLPllSSDHgbd4+bPv8AQ54qvPcCTYj7hhucDA/zmpvcLFsy5YLHIGVWVeuBjv8Ahximo5CbSq7pCVAYc8dAfr61WiQ3EmVfBbC46Y5zj8asui73cs6xNIUV0jP3zwefQDIOKd2yXoSWsOXSSEMWBC8854zj1xjNX0lLNFutHMXmszblGAOnOf5VEzCOcecksKH5F8s8F9wxg/TrT4nZ3id5bmNSSkyzMoLcHBOTxjOfWrRLJoJHDqjz+ZOF3OZAPmXuR6DtSMXUb8LksQQCOAeB04yeOO1MhJlifcGSTzBGpKHdkDr2yOc8USq4diZJInPQhN25h34qWAyQOAzKZCoXn5sgAenfj+lQSI6hpCCGON7ADLYI9e3bipW5jBLq6PhcH5STnpmoPL/0VVRFGxtsZkYSHPUE46DnuKgohdCQ4Zhk5DLjG7J6detVSoHkhpYi6EH5fTkce+KsSth1DR/vYXyD1UjPJwPfmq7BNpieNdx3wlI3JZRgsOccdabGirOpJ8sk7ldXUAZwvOMe3NVAUaPzGGSVODt+UBT9z6dKdM6ukUySQKOXkknDEbQNoTI7+nrUN2DKkrIysoLR7IyRtBYYO727ihIoqTRlHBeReMIVPJMhztA9cjv7VTYJlhxiM7WC4O1h1GfatN5d08xKIQ0u5PmwCWQ/N9QRjj1qocWsqTXkwmU3JjjTABkMgHyjHYHkHvmqQmZjbjGUb5sjDHuQen1PSqkiB3g8slCuAIiAdxGeSa1ZoTEUjVTvC79gxnoRtz+GcehqrIrFiHVWO4ZUjGFxk89uooa7iMG7hD2LW8quyS4RtxxnnJP59z2rPuX3TS73Y+YpGwIAq8cc9/b6GtqaJzakSZcrkADqev8AOsu62NLOIi2EUAxHuazu0x2ucXeApJKijDqq5H8K44+X2P8AOqLpy3XA/St/ULHzWRSPmzgndkO3/wBb0rJmtxA4jwQw657mu6Ek0Fiox2YKgnjByOKsRyszKuBjbnNRSYCtjtxTLfKuEJ5NaIyqRT1Lp4NN71IV45PPrUZGCM1ZyDgru2EUsT2UZqrdsyRqyEhgwIIr1r4QaP5mm+KdYnTKW+nSRQlhkFip3Ee4GPzryaVNywoD8xxgDqfak3uiofEjpdCdAiurfNjcWZj69K6uxX5iHIJByVHqfeuO0ZWEhQMWdl+ZGOdp789BnBFdtp8J8vJCKmP4SWyO341x295nRI17RQWXavCkDk4xVwThBja5/wBxsCqtoAR+8LMWHXGAPT8Kuj5+XCZ6fNgGqYI+h0R4ZHKJzs/vdfx7VW1BAixsSdxQ/IcH8c/pVxD0TduHJOeBgnFVLss6yDHQ4AJxke3rSZmtzldRjbAAZlyeVzjiuW1NSPmG0buOuOO1dfqHz25KsqEnDFhxxXI6myFsCMKoUqARnv1rLqbo4LxYivZyIynawIZBwcY7H+tcl8Pp/N0WGKfO+3ZogT0kAOQQe4wcfhXW+JF/dEsy4XPOeTmqvhyy8v4X6NdA4C6zc2meuBgt/SuiPwmUn7yNqKMeVGpIHGQB61aTACoSCrDHPeoLchAFTkH0NWbeM7cZ+ZeT3FYs2Q6NQHJxnjAJ6irMEYILcc4B7ke1RbfMAIALjjp1qdGZTyRt9O5qGUOVgZzj/ePrnsalRiu4qqnAztPftTQu5jvY4wOf8KdGrbH8vah3YB9R6GoYyTkttQEjHyknOantoXedNu44BbAGcqMn8SelJFH5RjmBYReZlmjOPlyCQPQnpUkcMyl/klmMc25dg2tnACj65Oc+xNWoktkkMc2+JEEQRkAXJG4Mf4voM4/CpGUst0qmZ2wsUbg7i2D8owfXk7qjinNzBO1j/pZWd4YlwEDbhyyn+IZznkYOKn8rbJZx/LOLeU7RNKwGMAlyo+8flO3qBVEk8vmQ3kivJI20HcqOAqZxubHt17daeptxE0ce396Q2SAxO4Eg5xyeD0qC2QRWibbgFH+YkoYxN6bRgtxkAhsVdVS48ieKIshHkmIYUEjqPcfh1p26iIEYNI7CQlkIYfNvHI9D90dvxpPmC+W0ihZXzGg3DkDkE96skBpMzMSXAXaSMDHc+5pkatFtDBQeQy+ZwccA54B/Cla4EUmVTh2RSwLOxB2+2D71BOOZWEYZHA/eLjkH1A6cjrU5ZI4WR5ZY3DnndsJyMc+3XmoLkxbdu5ElwNrM2VfA3dR6f1oaGVrojchR8TfONgbAY4A4I77eazpQAFDqYwQkitJKR8+cFS3c8fzrUlCuow0Uk23eSBjzDgZPHQ8Gs65kCM/XeV+0hpFGxSByqt25FIaKN1cLPaZgjiuGE3lyIRlHT+Igd2B/Q1FcrM0jtKWBW3dnXKjzQM7f93tz7U+QeYST+8wgmgbKmOI46Bh15qKQSKzeQVieVmwwDNidyCMZH3D0JPFFrFFVkTzo42dkY2rOV2g7dx4cdgwIPTrVW3uPOWGeG3JMkCOmHB3bQAzY6BuqkDptqRY4ZbIRWcqJPYs8jKmW2uuS0YBwGyQefyp01yPL80xGPTWiE7hl+ZSpY7Sg6nOCPWqSJZVuIhGxt9z/AHPs5UEHZHu/1p6cYOCaaDGQQ4xHGhAQMCzdcAY65AJqO4kmgsWdI/tKxWnmBnl5kbODH7jbz83UnjpSTbfMtGELFY4FZQ2P3alTuXGcZ5AyfWgRA6iWCFzESzj5dhxk+3tz3rNu4UKsZI2ZUOdqnGR6mtC4wFBChQSq+WCMkd+/ON3PPNU7goVlV3Lbw8SnBUcZBOe+ADUOxSZlXMAiify5SYwuZA4wTz1+tYWq2lvIm9GLcAAqpO7oePwzXRyuq3Dv8xXygqD+8pwSQp75HX2rOvHiDBYy+F6RE/Nkjpn6HNFN2ldFnLXVkyOygqdrD7pyD7D1x3qm0EiOzDGGJIyK6G4jwCF2qqqAGDdvU/j6VRnVVJPzqDyQe4rsjITinuZgMufvAD6VJAxLFScnrTpVG4kZx2qC1/1kn41aZhVglFn0r8LNPjX4SSiMkverM0inkbvu/wAgK+cNVUpdSIucrMVGDjBBOK+rvh5EB4B0ZE6Nb7j9SOa+U9eLJfXOQVZZnOPT5jUxd7nNT+I2tGRkfyAjDhWYq4yeMYHrg12FgvloqjeVXoS2D0/LiuF0MLBcRO8jIn3WDIfm+mPSu6tNpEaYLBR0HT2H/wBesGrSudTN23CptUEsxA3EZOR3PpVsgjALKPQEZ4qtZD92FieMNnGDwW45NW4njdBgbscZLUxH0W8JaORh8zqCBngEelZ12ZEvJ3L5hZVWCMDJX1z71rnl9hfgDqw/SsvUi5AZFGQcBmHAX2HtRLYzjuc7qO9VZdg8wDG1sc89frXG6kpZudzEZ6dPxrrb2ExBnfDHJOG/i7ZNcnqwcb0ck5OMbscdcn8ayN0cR4kiDKxUq/OSGPT6VN4Vy3wGsZATtHiWbdgdcqwqLWFJ3kHMaj5QpyPfNWvCmW/Z7XChCPEr5UdEz2rdbGM/iQ+NvLAJwUGRgd6I/NLoqkcEZz/LNIULJ1BGMYFXLVcJmRcFVwpA9Pf1rJ6G6LVuGZC3GeoHapYuWypA5/D6URHHHHJyfb6UsZUZ3cnPUHgd/wCtZMomQqOUY7cDOe471MAAhLkDLYTL9VIxtxjnHX1qKJCdhLY25bbjOPWpkVJhcBm/jKvzkxNjPTtn1qlEm5YgRhKzM0caEL5u7DMoU8DA6ZXOPU06BG+1Q/aJIWulIAQE5O1WO7HU9RxUabo5owELNMryI6nlxgcDHRQCM980qwCWE2+4RM9sgcQqHYLuUeYDnlD93/gXNXYROBn7KZhA3lI5jmfAC45GxByTnsOwqWBZFt4SruXKqCjqEHAIkYAckZJNCxeaymIQgJ5fl3DbXY5JDhR2J6Gp7WBhlbdY8qSiOZMLkMSQ3f73HFCQrlmNd0sqpIjOyGTzVG8sQRhgO3UdOtDZV5Uhk2BT0A4656+ueo6UseDHEx8hrRlCxSA7Aep2r05yBx7Utxl1kjXAnzu3BchirdMf5zzTSJuIYU+ZYWKwqmARhcHqMEk1FcQxrGMIWYnkhtwTjHQ9aQgpK3kwMwyFZWUDy17YB9x0omRghZnRMZDBucDPUjr0pWYxGAAK4Yuqj5SFDH17nI/rUMxZoiPLjUMP+WiZGem3A6D3pWA2Op8tAq4HmAAKewyDkA1Wum2guhR3XLfvZNuOOMEeueppWGVJfKeNFijhGGwevBX723oecZxmqjgLITDK3lCMyRo0eARnkE+tWrgmUOxmcS+WsgAXIVt33h7kcZ9qpz3AkSeYy+QWxIfNb7hbgkjt/wDXpNWKRSliKzQqESRJQ6tKq5MSnlVK8DByTmqN40e+eZxsHkJG20kFBIcDAHGcjIx06VduWRZgryK8sOA0PmYcp2JHcc5/EVRlZbd4HH2iOCPEkwBKpEkYz8/BLZzkAdxRYY24kOPLMm2XywzswJ4A7jgZKj68VHJGkuoQHakkD24t7iM7g4yflIOcY9TwVx3zwlsQ7Zt5S0tzbHyTk5LgfM2w4zgHnPSonYSxDeczGDAhUFmYMrLwxxncF6cYqrCIRdiaQzoZvmtWBbYBGGVsABerycDI7cVVh2vBF++8zzSSQO8jgZX6DBP6dqdNcuIlnmkMMKMHLy4UrufaBj0yBz781G7Lm73QCDyluYyVO07QAQykYyCGyDxzkdqVriIrpvKiIMK+WELEK2WyONuexY7ePXpVO9mRS5KozorM6H5SAcL2/Hp3FJKCt0snmSCB5bdQe8zKQPn/ANgnYT+NQXRQSSIcxvI5UFsDJU5LKe/X8CalrQZDeq8UchIxEF27lbPAUYBzyeM547VlhsGQQbtxfzASedh42gHqMd+oq3c3eJ5Io0Y4kMaF/mbcGwzZ6nOc5HYis58y2sZYP5i8IACS2WPOe4xkYqoLuUmQzvtR/LAkQEBdy4AUE8/WoLuFUGWyocDgckAjir0SF3lieIy5cpgnaRgcH6dj+FV7kBIeZAW4V1bk5xnd7gHI9q3RVzJmHzH5RgDbx0+tU4BtlKjptJrSuuLfZltijAIHGeetUNOjYyL/ABNuC8fUcVpEyrP3T668DoE8G+H0X+KziY/itfKnjkGHxNqm3gR3Lj9a+vrG3jsLKztYciKCNFUDsAK+UfipALXxnq8YG0tOWIx0zUR3ZyU/iKfh7c8JMSxqMbevzP78+ldrp2XU+aGfjGM4/HPWuG0KRPKxJsO0bVy2MDqTj0967fTnV4g3yZC4KjIO3OOtYS+PU6mjqIM7IwSjBhyMfdA7A/lVxmKBV8vcQMHHb2qhZ/Ose9EfZ93qMj/GtW2eBEIllffnJI78CtCUfRKICdxO1vlOSe1UNQVyAgKoS3IPJxW0qEooP7tQTx3HpWLqbOW/1as2Mbj1xntRJaGMXdnNauhMj8gsWKsB0BFcbqwCuWL8cluOvoD+PpXZaltDeWGC7Tlzg5xXF6sxJKqV3kkhQPlz/QYrFbnSjivECho5PLHK9ewOR1xW54Bszdfs9al5JJ8vWJLkNjHCuoP6ZrC8SnAZiFYBgCuO3pn/AD1ru/hRb7vgFqg4Bmkvn47fMf8ACuiKOep8RzloAcFm+YDPrVh2CLk84OVGetUYisaIA4Llckkc4FKVNzOAhOxjjJJ7jrWTVzoRpQHzEVu2TweSPapBghQ4+U/wg8GltEKrEucleSaJI49gyxBzjAPP4VCQ2WYmYEMPldUwGLYxk88fhUrKFKvHIFCJuckf60AnA+mahtD5O1WIJDBDuyep4H61JtuDY4tjCZmJAMhJUENnj2xxj1qiSQI+x44JQtxKIwFlJaOIvwQo4zx/Ie9TRyCBUcTyfZbjC2yIoAKbMbOOg4yR/s09pHgmb5JIookEysQGRiJDujB6hiO/T5u1LaxRGOSGSEhpmj2xROVaOJOQDGeFA5BA6iiwE7okTyfOqRBNsishwG3Elgc5weR+WKtRnyWdQqeTGu1Dj5yWJ5I6bfxzVLYhcCZkmmnC7pcHE23K9O2PXr1qWcy7ZpJIoBIJSYDgkHGM5APzEDd6dKAJCtq7GCSCF3t5t0AiydoVd25vTOan2+ajsVyp3eUIjyQeece4pk0i27XDzFY4WZcIoweQfv8AGeAP0qYhN5ZCd4X5SuT5gxkhMYw3fPbFMlkcieZuMrLLBGNvzAhsg5BP/wBbpTfIU5GTuKk+Yy5z6Drx+VT2i70Qr9rRB8mWPA9M9/w+tVtv7tcpKQGI3HIIyT8x/wBnjqetO1kCJ44w6SxMqP8AOEOznPHTH9aobVaXDuAu7IIHBUDPzdcjv+FXY5N6SyK8uE2lsOMbTwDnHt+IqDfKqMRgSeYSApDj7pyBnoCB+FTYZmTKZIl37nCuRGsZG4ZGdwHHy/Xn2rOmKuCbgKyMQQ2MljgY4+taV0UkUyRR75W+ZfKbJCEHnn3BGc9qpS4S4eFV+fCbUEvzbc53Yx2/XNJlozp4lml4w0hcRyMBhtpByDn3wPX1rOt5YbqCO7zKluqHckn7smNhjDDtjpWncI6yO4kwGhLyR42lpCchwOxqnJIcCG5UFWYt5cjhmkULyAPUHHFJDKU6E2UFvNGjXARbgL5rY5bb98DjqeO/60wqrzyQrgWzHy4V27gEUbT8394En5T79amlO+RbgsfnXyzGOF83hsk+gHT3qsu7zQI1iNuJ5/M3BsM6gAH2Oec457VRLKYgjlsR5UEd0bYqIfM7+Ww27VJwP4jz6VBdF5pkk3LIu0YIbkSNn94cHGzBwFx3q08aMITMkkEs1uY1SNs7duTx1wcMRUEn2aJN0Yhgid1jjxGB5mOgLDv1AJ7HFK4WKq5bz0TG5ZHiO98pwcHj+H/64rJuWkj831MTwOHQkLGR94e+MqCBzmta6EL3Bj8qZklUJJCOu5jkyEAe4DN7e1Z00qJPBJcupN0jW6Nv3GZhxtUjoDgDB7mpd1sMzCoMrQ5ETW9vH5BRgxaI4G4Z6bSAD9apfaWRgGBO9sI3QZ5yPbrWncJFLBEmYVfYi7QAC0ecKN3X7w7VnNny4Mojll8tf4ckH7xGMdQfetIWehSJYQFsm+7tjVthbI3SD+AnuvfPtioXEbxRuCCuFaXK4KnHzop7gA81M0kEdrJF/rAygYX+Ig5xiqd7cyyKZJp5GllVjMy8DyzjH09zjmrguo2Y10waAjOQqkLgYyKk8KKH1mxDEbTOqnPpmqspyCN3OcZ9aueGY3Ot2YVTuadQue/NbLYxrPQ+xZOoGeAAePpXzN8dLQxeOrpwG2Sxo5wfbGK+mphgjdnOBn8q8E/aHslTU7O65BlhAOPYmso9Dlg/ePM9JaNJP3u4yAFnBHDqR0z2Hv3zXb6JsCguCVQhRu47cDjrXA6K4DshG48YXJ+bH8J9q7/SnWVUCldpGcZPA9B6moqfEdbOrtCoVA7gYB+Yjnbx0rQi5XO1cnrubnpWbpxQMARnHzNzncMVdRhtG7k/3sYz70yT6XnwkZaPPyHgE85PTNZOoq0hAbcSARnIHTnArWuCSrBMDOMbsde1ZF3xuOV455HQ0TMoHMXwZ2YIhyMHO773qM1yGpfNI+GA3En5jgdOme1dbqDea7FgM7sMFOCorkNUIAmCnKDrxWK3udCOD8SO6RsVY7xkhTg9uetes+AbcW/wGgOf9fp885x1O/ca8e8XErbSGVzvKEq2cn/Jr2rQEa3+D2mWzKBt0ZQ3tmP/AOvXTE5qvxHmjKQ8bkHAXG3PrWlbRIoICg5A5LZJqvDG7XJHQAfKDzk1prD8oAxuQYOePzrOSN0xehwp3Z6Hpx/9ak3fMoAGd3U+tOMarjPPBz+PpQkez5gR/s1FrFli1VAYw7EpuGdwOQO/Pbp0qXayzyOrMGY+WuOmDyM/402JWaNgCxAAG/oM88+makVflVZV+YooOwkFyP5UEjkhVYo4rcC3LrKPMWT7mDk7h+B+maukbnka2WQtt3+bKeMgcH3Xn+dQckkAxqVRo1XO0kHn8cjP4USkfY2DwbbaGLcsKkllJbAGBwRjJ9utFxlg7TFKgZQ4Id5MsybgCAc9lODx1yalDSO7RKZAgi8xsfK25T2b1OMYHPzVG0UZkaIZCsnmRrC2OR1DA+pP8qmE7iDzjA8hdVcQBgshkznG7ngcZx70IROGkJ+UFmCEruYfN0wrDuc5ORjpSxtI4eeCVVnCYG6PckbDllB980kvRJC6yP5u9GYchAvIAHU9cE+tEpHmpJvnWNkJwy/KoOOvOM1aJYTgOJRHEux1BUheQAc8knk1G8yFnkknXA6HleO+e3WmBYooUjSXd5Y3K0pywJ7Nj73foOKmRwBEu9JFJYGNV3HgDjjgdc8/0p2ASN1O9cOVyG/eMCB2wRjtjjiqN5IpUIcEjJkDEBnIIIwB37H8KtxhlkB81JGbBMq/IwwcYI644qpNJJGVYNkByrbYd4XK9ee2T+lKwFGQ7pF+aXGwqBIdpBYFgNw4xz1qnOJIoUw0ghigAGJBz0G1s9ehOR6ValiAFukyB9vyEKGAAznj1qlKu5i5O9HVwFJw+0eg6HJ6dOtTYtGfeAssqyhWYELKvdu4Cj2yMVUuQwaaSSVY0gO6SRsKXGBnB7Z4yKuSTRM+x450LL5gRlXkoQpPPQZI9+KhKyXDSR3UXlsxMcmMOWUYwy+w9xSKuZ06MGcyq0spXzEVOh5xx6HofwqKZI47nAfdPDn5sn5RtHHoetXoJ/NkdiYAZGyQpIYS4469BtI/GqQy2JWV/OC5kVzgbQSMnPccn3oQirIhjidVXIACq+4LjGec9uuBUSGWGRlZkZk3BRnJ27eMnpnBq4y+ZOY49rEv5qgDLSLk/Kf9o5/+tWayRiESGUTW68boyDvUZHHqc4H1FJ3AqXTCHETB1Rk3JIj4Yyrwdx64wV5rOkl/egGJhlNpU/cJAB3jPcY69auzmSG4UF0eFI1eWNmO4sDjcF6AYwfqKzrpJRFHGXZmDEsGHzP83Bz3BHaod7jRBNP5jTqFeYrnMZAwSeM+uee31rPEUiqyqgMm5QyEgKCeB169DViSZXKMsCOmQ6NGcfNg/KV/AE1QYr5TY+UGEs6Ekbznqh/z0NbU4tbj2JrqWFUdIRGAqZCxkZZv7x9x3rImKsiOUfJQdWzye+fSn3GGhWQkBmG4OODkHB/A1XeTfGcBdqn7vfmtlGwyvOAFy4G7H6dq3Ph6gfxToyuvyNfxce24Vz78SqpOQeCM10ngNwvjPQl7C8h/9DFaLY56z0sfWE8n7xuRwa8m+PMQk0/Srg4IWRkb8sgV63Og3kYxya87+NVur+CXkY7RDOrE4ySMEYrHocq3PnHTjIjO6zINhAVW/iyeVx3613mkHZGiMFKFTkL656A9q4OzIE4Ct5YAOT3xj+ddxoxjMERHyg8qAeCehzU1dGmdvQ6/TlxEQHjGP4iOcenvWiYA4UlwDjow5rN07LFd5UdMDPFai7SMAsccdKCT6WnChHZSGLcAHnI7Vk3QQOwXbyMZJ6nuK0pnVASAfTHc1kXoUAcru6/TIxx70pmUEc/qqlU2Ls+bkkdQPr61xerEozFmIx1wRyD7V1+rHghCY8DB7knua4rW9rDKjKqpC4PJPvWaWpujzTx07DTbjCoGKnbg5Oe1fRuoRC18EmHp5emKvXGD5YGK+c/E2Lm5s7VSzNPdxQ88HLOB07jmvpLxg3k6Dq4QfcgZBj8hXTHc5Zv3jy2JESZCOWHBJ7cVd8xXGD1xww6VTjRPKiZZG3kZIY8g1IrJvAztVc8/SokzoQ28dwoW325LdM/yqwM8L5atx8wzUZwUAc4UjrUkbYLbyWxwB6ismWWG+WEqyktggjPX/wCtThvKsCMrjGN3JOOn9KYo3DBIKlQTuHH+eat24LKrIqKwIDZHP0+vf+VTy3HewwwkuhYnMgCFUTPJO0HPbHepoI3KrJIPLXJTeGwFUgBjknsfSpItpIaMvGpYZZTw7DvjtwMfWpU3OrIkLKhVyVZBjacfgMk8+tPlFcfAqOYo8sAyjKs25ScDGGxzng/jU9iytFa+TD5aSeYmMFHDYJO0HnrkcVCrx/aY1FvMDsLgryikHDLjPAwBj6jipYWkRG/umMFHVcpIW5BHofXPrVJdiWySNElt2haJYN2whRKSWAHJ3e1PUF0IH2aNJX+frlRjA2E5BY+tRo2yGQLCE2om1FcBADnJDYzgUOdnysrtGzB92/hQejZ7Yx061olYljllKny2BYSAsHij3dB/Eem481AGVDtJJbOG3KEZjj0HUjigTNMsbqYGkZchlkbaVzwOen1phUcCIrF82VwSxOT1J64yOtAIkJXeyySLv2Z5AO/8R24qpdEO2RFtVmMhCy8qQM5xn5u3tVkErAyukLsFLYjUEhTxgDuM1UlJZyyBCA+Dvi29Mbhkc49D7VIzPmKnJt5HCtkheZGUkkgsOzbiTg9iKrTxgrKgEUrCPDhc/Nh8EgdeMDpT7lHLIXmljQEgShgjFt/GT34AwfY1HOGfbCXKuGMjh+DgdQMdenXvQUilcykb1LAwyBBIJ34wOAxPqCD+dUXybpmEhb5jvVG2rEVJIXB5O8H6VdbzArneIwG/dRAKflJBUjtjrx1qrI8Ud3CGnVZS0kqtIOAFX+IgdsipKKMbyJbGFpILmaNVV5NhGcsSSG6cIwwfUVFPNi8Nq0as6qmGJ2K5ZuF56sRjjuc1ZdysKpMoVW2OikbirAHII9BjjHrWezR5jgYSyTRjzljY7pIwGxu3H5eB75xQA5IbmK8VZrtFjKCWVFQKTL5n+tJzwCBjA96y4Q0bMLJJ4J5IVulhkKqkMfKbB6AMCxx/eArTAhEUKxCEuu0p5LAhVIPzLkc9cYrPeW8iKrH50l2gMUc7MGZNyAZ249Tnn0oSEU7ny/L8tCIoxlUZvlIiZSCFHcknOT+VZl0izR8NIF2qqsRjfgZ6djntV53XYI4zI7JsSOQ8ZUgEH1wSCD296oLIJIlEEYL8BljOdhLMCQScZ6nB6HFS1cEylcySKYA5il35dWRtrIvVj7ccZ71kXXyWw2giJWOI9vCjJ4B/HP41sSyh7h4nJaFw2AqkuTnhT7j+tY9zKUkACkhcMUHTcfX171pS7FlKV9yoC3AG0LzwPT86gA69T69qssAC4cKHzjI/gP8A9al8jEuF3Lghcycdf8f5VuDKcifu8s3TsetXvCk/2XxHp0uWwk6PtPswqPywpDLsaQkspPJXHc9ufSooY4443k8wiQMgjXqSCecntjFNGc1dH2jOvfsQG6+1cb8TofN8E6jtTzCm19uOuDXYJNHcWsMsYBjeNWBz1yKw/F8Kz+F9VjIzutn49eKyOLqfJCosl3IjICrtgMeBn0B7e5rs9EZVKqscShBxtfj35/z2rjDF5GotukAB3EYY4DY7/wAq6nQJMSLBD5DKFDBixwGPXHtUz1SZ2LY7awkH94Ng8ED8/wAK1om+T7wyOuG61i2Egby+7KOhGAfYVou3lkL8uR1wCKSJPpiWQllJIVWODWdqDtsADIME/l/jVyVwcqBkZ6elZNzIC4TIL8ngVEhRRg6sFG5VIKkbtvOenWuM1YhQTkbiu1m7flXY6qWBdiTgjLEH0ritbjEiBOQudwI65ojuadDjbCL7V8QfC9oYiEl1AOzZyCF+bp+Fe7+OZceGb9jnLFVPOOC45rxjwNH9p+Lmi7kKmFZpc5+U7U24Hoea9W+Icu3RreDqZbgEjOMqATj88V0LS7OV6yscRCTkNwS3r6VIQrYwBu9fSoIlZ94U9Md+PwqwBtUKv3hjgVnI6ULgbcOfvd/61LGVOFdjuY/Kcc5qKMqceZyh7+lOSTy5FTcAwX05KipsMto5LZTbGSMhSMkduT+VPtFjZl2PtVeCGPUbcHA+tRBWchMZGcYU5zj+makEnlKjHa+AzCPGclRyA3400hXLEZKeW0blt0ybYmwdv09P/r1Z3PCS9ysrIPk+VjtK8HecdMc1TVY7dIQIzKhKx+WWywOQqkHoMdT+FSo4it5pPMmttnAfcWCkkKAcck88YyPWhgWJWcxXeYPMfEZMcO5FcgYxnPI9qtvu80+SsKooILSynahwMEqPfg/SqzP5u5fKlcjLlWZULMp6H0BxnpT14bENzMWjR2O1dxfcvDA9GP580ITLCqhIIdVLYZlc9AeVHHb09qMgbQk5inHzho0zk45LDpjngmoULuboEkKjbBuUHAB4IA59eO2aWRv3ixCGMAKMADAlHUquOTx61SEyYTeasrvLbgBm8uGJegGAFxn3xUEsqRy4kkeIKQwRcLz0x7j1FM8xxMfK+zngsIsqHUYzk+mADzTEkYRqyMvYMYxvTJ6uGPOMcZptAhBt2uhd2+YsQflXPUAGoJ3G9X8pAoALO754/iGAefp261ITvU7ROcDOBKCoQY5yememKpTy+TH9oeVGiQBiSoJAPG0cdT0z7UrDIblTCqrJ5CIziNWU8JwSAvrjp+dZ8svnpH88r+aCMEbWHUEeoyamuZo4LZgLuN5owspadWIjUnr05YZ4x6iq88p3MWuRIxmYIPLywUDO1cd8YpNFIgMhAAMcbRIqOCx3ndjBH05xmqlw7pEscrwebLvAUHy1Ydz0OeCOfbNPZ4lO9P3f7raHY5by2+b8DnOP92qksVtIsTnywrEhnfLbyy4OD0G7FTbuMZNNtn3RHchVjG6KCcYOCDnpjv3yKgkmeaWMRSBtwDfM+xQRw3H0OfrUikkM7RsoZgBG7KFizz29CAoHvVG4dXBe2Ct+7fyXZd43A91HOAcHtxSsAQrHIwnZJlEqh2DDyggXOSRwQVHH61lmaCxhjvZWuLWKMDDbSW3bcc9d5AA+gBNaKRhtlvcbrg+W0LqVx5pIxI/J+4xPB9qqs0iNvcYNsgUeUTtIHJ2r3OeM9eMGqsSzKHlxLb2+YrG5fzEyhyj4UEEdwBuyOg65qirrEZJbdIigYs6MRuAIyCfQliDjnI71flnaRABMvkNamYnYT5m4YXPGRwpyCe9ZgKtcOzmO24DRsFIdiCAwI79Nv5UrW0YIgu3aO0hW2LLLGyuGifiXuSWPIPPX8Ky3cSSB9mxlBXAPU54JHX6+tXC5a34ja3WZcLC3Ln7xPHZTxWfbssi5mkbY64CsBuJH3Rn0rSGiNETLAZSQUVC5GHLfKxwQRkcZJqaWONLNQsnmZ6xFSPLPGCD/ABdxSWkEKruxsCDJOCf4gMj2/WrEoXy2UuEUMSkalv3gUknJ6ZA55pt6jMpowiNG6Mo3Akg9B6VUmcow2qMoT83c1rTRCOCdZdrpnzPMAAIOenPJzkfrWVMpKlpMtn7x6EE9qpMW59SfCjVf7X+H+lyM4Mtuv2aQA5Py9M/ga29bXfo9+Mhf3DgH8K8j/Zx1ULJrGjO/DAXMSe44b9MV67rXOl3v/XB/5VL0ZwSVpWPkW7Ob9t3loFLbVU5YHoBj9a6LQcC3jWWB0C/KwZcZyPvfSuenicakysBu3sxdW+baD/Kum0qNtgQnaHG4BXD7R6Z98dPes6myOqPwnWWcjDarryAAzY/Krxc4AIzgdSaoWKgsvy5bGBk8H61bydzboyxz1/pQhH0lNMVjcrggjGDyc1lTuNxbnnsegGK0ZCEUYU/Mfyqhd4CHY3yjHP8AOstxx0MS/Vl2mPqBgccEGuL1wjLO+fmOBu4J+ldrqA4O0kZ6c9K4nxAG++qkhTzu5DdsVcdyzF+F4DfF21ZSQF0+4O08f3R+Nd78QX83UrGMbSIYske7E/4Vwnw1/dfGC1jGMHTp+M5wflrq/FlwJvEF2QdyAiIcjjA5/XNb9Dlj8ZlJt2FdxG3G05xn2qQZYSAHgn9aiKgKqg9Rn5e1Cv1IC/Kc4qHqboeiMzbjgNtJyOvsKmYqVypOQVzxkqMciq6bRuYENxjIPTvUwwNoyAJDgHP5nFIB4fG5oxktnkDaX9cntUkciwH5ZlRfLzG/Ixjkn24z9ahUq7vFHvD7C7/LzjnBA6evvVpHiZVyxlEigqw4VyRgDPp1p7AWFjLSFcl3dMJ+8yXUfe56DoKcH3LE6GUowYq7Jt2LgYDYPc4AOM1X3FYIxdTqEYhWMQ4kbPyZHr0zj0qaKQ+bwpNyz+RPG7+WU7lkboQc5H0oAnnWOUBDHFIQFBQMS21u5JwRgZ61PInlROha4QQqsikuPkD5AX2wSDVRRGTtDb0kfbufKmVdv3Cp5Izxn2qRFMtmZShkmni8rbI4UkBxtB7ZA5H0oQFgkBJFLFYYINqzZO5c8kn1xio2GUQRKrxliCQTvK4xkHruIH04pGyoRhMAsjlEIJbcndTjoTj73TtTpo/nZ13pEI1XKockAc/N/UVSYhJVDquxsS7WCi4UBi2OS2OvHFQxKUlIVQWYDhPlB9ue3emvMwWSOR4d78K4fLj1BPIGfSkgKhnYRZYqqqXl2xgA/wBD1B5oAC6bJciIhJCpLsQUI+8dveq0jlJFbzkGVJdfujYvTaPfvmrE8kqqXVhE4A8tlCtyT1HbvnNUR/rJISJZMx4XBXZjBzn0znPFIZBLM0kEqo6B2VWJikDbgVJwB3x2FUpJpJI/O3FkKswLAKWbGCQDyuCc5+lSyokwZGjRViVZEaNPlEi9PfpVO6+e5uGIRpBGMsTtbkHCNnseaNxjLibyjGskkyF9kYkbksTwCT0zkGqFyba2CysAoQ7dsi48mTcyr8q53DkcenNWbhCqQoXEQDCOONJPQdTnt71BdXWySRhL+9VNzEp1x8oPHXFK1hlaVhHIkNwx85WcElAisQMkgdwTz+FUL4PdWYhMt0GMYWOe0GxxKwwX2AjpuGQT0FXJQsLqJWDCJQp8wbiSeOD1zk9OnzVVeCRJLfzIi8iS7IpXJYtvAL9OBnb9BUgMd1NwscEqvhGhBbgybRjazdhnnjPWsuZ5PsqJEqW43PIxYFACzAj3zjP19q1XxIjSTOgO5vNTH8QADsB3wMLkVXk8tI5zcBWjUNtQs2Gjz3I6HGefaglmewEbySDEccWVTzVwm4ZOSOmzG3qeR6VQ1Bbi5/1TpKrLvjwoBbaw3dc8cn/vkVr3UCi3lG6HDqYEZiCvzcDd+BqrqBgMEjOhGxiGXJwAp4OB2GM4HXikwRzE1qG3ku4CjiRuVA4wVYZ4wR2prJ9pCud5whjO44QuSTgHr93sB1rQu0hFuXWBzGybiMFWx1UYPQ45H0qF44lUOgeRo4xJHKODEcAgFD2DZ7GrjLQ0IYoAYYSrL5LoyKjjbvAbnHqfb0q21vGkKzHcI0TDJ94beCXIz9OnrVK3CznlF3FtpKtyW9V7g5yatoWlWVImuMxsArxr1AIA47knGV9hQwKscdu0wWTbKC+7eDgEEDGD9Aevc03U7FoBNlBIEOF8tsqPXdjuBU6y/ZwovJFiizsl2w52H1I64J5IA61WlzbW7hY48scSEOd+489OOOxH51Wu4XLvw81ceHPHGlXQkVohL5MpB+Qo42ls+nOfwr6a19gmjX7Iwx9nchge2OK+Qrw7f3iIVThQPcda+mrfUTqvwl+2s2ZJNMYOR/eVSD/KnI5q8dbnzXeMG1k7JViONuYxuOfbp+VdRpUccaARJtDMGKlMBX9/Q4rkWLG6i3x5OQeG+6OxHoe/NdtoEBCFm5zw3PPA71nUWyNV8J01qP3aGRQoC8nP51aMipgCXYDyAT2qGDb5ZJJ3DlhjPbpUhk6BkUYGMAUgZ9GOd8xxkr976VBKpTBbJJ5qUzAlRkYI69vrTXBZVJyUY+tZgYeoLkHPYZ4Oa4rxJE/lryd3VSK7vUNqlt5VewHUH0rjtaDMkiRtzg5+lOJRxvgBltPjDo2QVM9tcKQepJXP9K6e4bzbmZpEwzOzHA9TXF6JKLb4peFyd4InnjL7eMGB+Peu5JZECSfO4zy3H4iuixgviZV2qE+bJbBx6YqOQ7AM4BfHTnipHkUPGNoVicqPUVHKUG4hcEnA78561NjUEO4kgHcFwPqOlWFCMMMSox9c8cYP51XVgVKlpOuOOPx/Gp4idjMG2Y+VcjpmkkFySF2aOMh8RhiyqAeW7e9TRFWCvG0kgzh0KA73zx9COf8AvqoHKRoWLyLEo6q33T/XP6VMA8R3AjzCSWB4IHReOh4xQBIsjW5ji2hCozEFJJBwQQB0yMU/cscRiE4ZocBkL/NtJyNwGSCf60R4QgK2YUAGGfccjgpnt0pLdpWMZZIZkIVfkbYWHXcc0hjy7QuZchn3EqqAq2McEZ7jvT0IIVVaUjBj3fLv3Z6gdz7+lCrJJCVLuoZc5AG5iMjAboefx5p2WeSGRlkRT/rMgYX5eMj17UxDmYTL5ixxeW+FjGT8q9TnA65A49zSozeZApVXBAICSkkdwBnGB9eKapLrtA3yA4+aTcFJPQ4HBxULMiRlScxRqRJGB8wz79gR2xVCEkLLDujTy3bJcZDAMf5nmo0O2Fyw3FhtOfk69WC9GzxxSyMQZkUMxJBeSHCIF4wQnP4kGo1l2giOZCcl8MC5Y9xg9B05oGOdVQxR/IiIpZyAc4A4AX09fpWfcKwXa/klmztkydvQYDEds1ancdQZRGchlcArgnnJ9Bxj1qpu8tflCSOQVG5gOB1Ht3pegytcxk2+zaJQ2xJMOQxwfmGfTPfuKZcvIHP2m5kmGBzIgXLc5b6f570XPPKeWBtBaIHd5g4IJPXjmoZVYCRBJGVVyrE8jOAcD6+nakBWaCLY0SBmQoWUMgkUEfxDPXqQB6ZqKcb2cPlVkUgvGFEi7sgHnstPaQSqBJG6EExqFOxcHp156g9KgmCbYhGAYjJudtpY4IPYnpnqRQMjuWCR74RvZnCgsOUAPfnuAPxNQeS0yTQls7zJGI4P3ZWIrg4/vNzjPrU43Bo2OyPcwV2jTbuYZAXnt05x2qnOVuI496gNLiQtvKbuRuAHbnH1qQGxgT7pJtsahRAD5mVkBGCmeMAE9O+KiMaFAXR13gKfKl5TJ4GT24xxzzTpNzG5EiRhzkoAOAw689yByacyqzOk0hUIwZvJUDG/GGwck8g5+tBJUBjmlPlRyFM75GKrG8YZCCHyeuRnHUDFQXckcNuwk2j5BnacqQ3BJ7n1z2FaxVlglWSNY41XZNvUE8fxNnqME8msjVn8pt8DrbSeYAZ2Hyp+76nJP8OB6UMRz1zvimDQuJHiO0oZNyBuQVVzz0x2zzxzVWaOB79hbmXy15O0fvIzg8AdO2cE5x71fnwojeODe8qlU3ZKY/iJIOVz2PrWdNHGrOkcpCzKoAfqGYEHgHk8/rRBo0QtrHBM6rcbg2QMRptYZPUE9eo96tW7NIHkUzNIhfLmUoWKnG/1U9arQtCZRHLMyQxZV1J2lABtO09TggY61KvmzxKEYt86qxkOWZTwTu6HtkYqpajIpoVjO3OH4V1fOcAd/Y8EGmhIthmnQrAp2hS4J2g4kIzznODg461LJDKY5oZVQRqpRpCCrybTn5R9ABn2pJDGrGW4mb7U4aQP5YwGxkMR/EMnsKpMRh3kJWRkuFP2hOJNh3bj7+hx1r0jwB4mT/hXutaNKxDwRyNEOmEZT/XNcTcRqbeNzvjncBxKTknI6hRjr61H4Wc2+qX0DEsLizlQY/ifGR/WqvdEzSaMq1VjexBAwUpufBxn1/HFd/obAwqEZnBAdmPU9gP5VwVvxOiyBsbT07HvXa6LujhQOWx2HTFTV0ZMNYnX2pDbUAy4+YAdqleOEtmRwHP3irdT61WsZQ3GS5IxtPBJ9KvOUZslW+irwKzGz36LExHzhhjrUxQdAMZ4AqZIgFG1AGPY8VF5phAWTBP3c+9ZNMVzFv1Qb+fbp1965LWoyEJx2wwFddfgu24Ec8g+grk9aYRRtluMY4PINVHctHlkjGP4m+GCGbeLiQDBz1jI/rXod1joq4UfLk9zXF6NardfE60VgSbSwnuRn+M/Ko/ma7Y427lxuA3EE5wPQetdCMepUHLqTtLcjAGf1qNx8ylVORhSP/r/AK1Ow64AJPr39gKZkjd8pCpznPX/APX1qWtS0RD5pl583J45Hf8AlUyMYmYPKu3Bzt5B9AKgwNzMcHuR1GPw9aki2jGGwiEnocAfhQMmA8tyVUR7upLc49B61MhVlDC5jRTj5sZCjPpjOcdKiRVVSXYLIUwXHJQHt+Hr61Zt3USbQxRgRtYgkMcZyOOOPWluBLH5ku6VWLuEwrKA0sfHIcdDnGR1qYFCDskVpdw27cblPQEjPA69eBVWJkkxhXWdgSythkVuThsdMg544qwnltiMwGQPtZxvA3KeMl8fMw5OAOlKwx7WwQzBIZt2eQX3HJOTgHpwc5qN2MbLGrQs8aEqrvlyGOCxPpk4+op8gDSb7mJUm3PjcS4PGAvAyARzSri3RoonZI1Bi+WUExYHK9Oefyz7VQgmkjbZwZEZmbfgHcc/dJ65GBimJIJtht2m88tho5yN69cZHf8APpSiVZYRJEV8xhhQr4OevIPT61DNHEHMdwbd5BgFhIRs9ue+QMn64poRW849EeIPH8oLoSAQeV9z9fSh5FYjc7FQWI+QbVPTkjnHSnXK7pzulyAxV1ceYxHsTjA71WbdEVKOroyZJA2459O+fSgYSszqiswjbG4iQgJxwMt1x6VXuSYx8jjLgtjG4cYBY+o6DBqeZWCxo8qFMHDBghIJ6f8A1+1ZxJzuUoxVzkY+4Pbn5j9fyoSGTzqMuo2HcysWI4ORkH079qgd45lWWQIIy5YFT90ZwOR3pssUcbttJJkPyswzyBjOMClZAApAZc9kKjI+nc/SkBUeZgD5qlZZCXzncowMAgnoAR0qtMyCTeTudsqELbUOeAB7k9+vNWJMMnlzqpiySwQ7iSein2weRUUkYxFuVWUTKwUx4JBICj8OOeopAVJssj+XsmjAKvKnMiHjlAcgHP5UPIBMDADKn3kA5YqFzhwcbSTjB6GleORZlUT7pViKrI3MjNuOSQOMDPcZpdqPHFmOOZi+YyZMDcDgkevPQcUmMgWEx2se6GSONAQZJcB4Wbnawzyx4zjNPZljubYS3RtpH3PAoAKyoFG9icYGM5x7ipIoTFOEMQdwD824cOOBtUjng9ulRraxs0UEaoQZGCx79yL8xZgT0A45H0oRLDdiaXyApIlkEsZypUBQRuB5JIOc8jng1i3qyfbJVS2EjTxMSWRflYgKnGeoGW561flkjDqsVzKLiV2eIsxmEb4BCvxjHzfdzxjFZZaO3jdZrhfImKqqkNIS3GFYY+QluQxwKHsSU7zC2m3aREyGI+RHgsMD5iMeoJwOnWs+Jt8xMEu6ORsxu4xEwHRQ3JZ+Pvd8Yq1dE/a5IWAeW3QR7S+NrYLK+eflIbFNjgBnDQSwypHKcRzOGXOONg4O1PU+tRoWirLGy28kZiR5iPMUyqA4XBBIJOUXI696fcxM8jPHFILMZw0LAqiEc4I6gnJ3EU2AKIHmXyXllZX3hFkweSx9cN3x0zik8hlZWjw4J27wmMDqqgk/dyOuMVatYoI1i+zOtuzyScSRiTucdIz17NnI9aU20c9xNEkole3ZG3KS7Y7kBedynjntSeYwG+SRcy5ZGZgGDfxDGckZPpUttENscZWNSwMbyRttcggEOegwDkbuT0HNHn1Aybr7Qlu90y7C7NG4x84cAbgueR79OtZuissfiOxOMDftOOQc8Vt6q88sbOfLmQgNKFyCz7uSRxtzkcEViRrHHfWrBXDpcLhmPbPTFaRegdBt+j2tzOjEiWOQ8qcYOc/lXU6LclrUsWXLcscffOeorB8QJt1W6bJKv8+fXIzVfR5pPkEku/OBHEGxu47+lE05RTMqa3R6dayxxwgly0gH+SKv+bcTKrxo4Uiuf0uRRCvmo2/GDGvXI710EMM8qbiyDsA2cgVkiz6VV90KvkueuetVrnY6nZtDdG57/SoLYgZZc9x8p5z60t04ZAysCD3wc+4qdydjKvlPLqwwQcrn9a4zxBckxAuNuONxPLV1Or3LJgN2GMDniuD1+dZYTu24znnsKEtS1sUvhnGt/wCJfFN6o8xrPTVhU45BdiSAf+AithmDCPhvmxnB4x/Sj4E2bPoXiS+OMXd15UZJ/hRSD+ppzqY2QIpX5eSDk89vet1sc8XqyKRDGMSbzJtGQOpHHeoQokmfyyvHQZ9PbuKmDlhsywKnOc4z6Z9ahlixImNyMMBdgPIx0o6miIyB85X5B8oI/u+3rTpZEUCLzArFvlZsgH24+maVsOSnlMhGS2eT9KTzcsmAr/Njj6c/XHSlYZYgkXIG1VY5PclT9D1qcStGGL7IY1UqzO33wSCSQOgxVKDaVVyPM/u/LyC3cZ98ZxVmMRuqxSttycCQg8HG7GO47fjUjLC7GeFZWaMoSCy4UkEggN2YjgDFTR7lWBZAjhG4ZiOHx97jjII6fSq9s/mxOXGAOQThiASSCOeOncVMG8y2jnQ+bHLGZAQAccjGUPcjPNIZaUhmiUqqr03hzuYHJ/Q5/A02MkIJE8tWQBQ5bAJHAz68nrjmoCC27ysxyMSygth+Omew46e1KytuKK6RBjkAsAAR164/WqWoi1yGcxSRExnajNwcEYIzjke9QXDKB5kkomiIJPCjOe2Ryeh5qHfJ9lDtlwucMJOOvI+lV32SAFYQWbggHAU+wpisOklDMpdI1z94sQcDoAvt61SlKIJHRlM2MBOQT0wRnrSFAmwho2OTnkj16Z6VXckYDMrEgfIDkAeo9z/SluXYfLOkgZXZAxO4YByRjp7DrUAmWVPIMuIk+YEgZUH09T060yVlDCJD8vUDA69vocVA0qK6hnG9ecHOCPU+h9qYizNEgYsXfsoG/LKP/r+opsuGZiCUDAhCVDHOMA+xHrUcUuxz5Kjk5Uufut71LJnyWBCOxXC4bO0Zzn279qAI5V8skkfKM5VBwzY6Y79M1RnH+kRRkSNJKrK20nK8fMAe2OOtXpERZiqkMpHLA8Kf8/rUcgw7MkOzYhZW34IbHTHc9KQGfkSJIUk/exEk7GwRgep69vXNIVfcG3xCQ5BeQj58gEfKP7o4HTpzmp1aQLlwu9TuZnxgZHIU9+lV7dBZ+RbxxShY0EPlhd6YY9SDySPX0NJgEdvhB5aNhsy7F5YcFgVb+A9vpUNzi1s5FyLaKUszuSGZMj5mHb8T6UyQwfY4zNO00bLGJpWUKZHLqiMcc8njaM4HXiq886C6eRNwZZScpEc27FQOp5JOeB+HalYTGXDzSGDyHuVU5dT5I8nBGQ4PU8dCPxrK1aR0ePc4EdxJuMUL7tiLHgs4xnGQT6c9eKvS5G2S0MSpLMYIJIZN5cHjP+xgA5HZuKykA/dyxebJBHHLKwaMqwAzuJGRnkZxzjjuaLC8zOlSTbkAfuomIDLsYFTuVlP8XDHA9anuj9ruJJmZTLcHzYnnTaGOzhyqjA4GB1+YmqU8kk8Nuk2N5i+0GR5CqTKX4C/7RyfcYNWFItbWaK4YOfPLZLl2V9mVAT+7tOd3TOfaizSKLVjY+a+I5YFWUP5mVwqkkHCAdMAjj396tXoi06Z1AEpClXVM7RxhOnC4ZRUEmpxPabo0treLaTPFCu2QgH5lUtwVOSxxz0GeKoxK9s9xGts8RDeXIG+SNHH3cYzuAB5I9vWi3XcFruTpqHnABUDPLuKb490jtj5un3cAevNOKeUkb2tpJ5aEMyRgO0YBztAJzluTg5wKphI4mYxbkWUtmOZj+72nIVxjktnIB9KHmkiEcTCaDzgJBIoZ2Df3xt6cHB75xT5egyvqk0MqutyCXfMkU0J+Y84Kux6gAA4A61jKwOq2ytEQyyr8mMd/5960L6OSC7SFYwI4hyCcLIcnnIzjdjoOhqhCEEySGJ0jEm4gAnB9M961hHTQUpJWNHXvnNu25HOGU7O31rHsv3N2zkMwzkqvXjHNaFxKPscsYbdl1IH49qyJmeGdZonZSflO3vzRFe5Yl+7U9T0Sxwku9Bl5QC7KSccd/eugW5+UbCApHAxXJ6JOsqYhflRmRO4I44x1rof3c3O4DHB5rnWm4z6QWXEgOAXHIbPSo5pQYhvbknA55FRbs7goXcOCKpXT4dhuG4Dk5qEwZma1OzbdiuUPBVTzXnXjGVo7G4dXHygsM+np9a7nU7g7GVSWAwoPc15t40zcW0dkMMbmZYRg85ZgK1ir6hJ2R6/8M7JNE+HGm+cCgaJrmXPUFyW/XNc5qKEXUjFRE2crHuyFz2471qfFa9k0TwJZR27mMfaba3OO4Urkfoa5LSruVr7WLa5JKQXeI5AedrgMB7da6OX3Tmp7mgk3lo/3jHkHc3YY/wDr1GX2o3JC7QH5JOeuf1p4ZoyRkHBwOaNrtnYVDn5sA4A9Ofeo3NyOZcRIzDsRuY8H0PvUcpGA6KCmeoxgn6elCuAQjOroTnGe468npTPOYzo+0fJ8qgL97HGMf1pPQCS3Kq4cl8LkjdypPOT/AIYq8pcEvmIfIAQ+SdnXp9envWbbIqmPcFCL75AySAMVZii+RWjKswAVWHOHwSTz2xx9amxRYQK0iyOjleqgfIyg9CwPBxzUwUu8KmQSuQACmPXqO+MCq5jEqptd3WQFdkpPGeec9TU0TGeQE7DI/wAhb+Jgufy6kUhk2BL+7DowYD5fmXavOCD9QKdCfMOViQORiRWXjIHQHp9aYZcyIiyI+7EbKw4IIAz/AExUihdjx7fmYY2btuSOTkjj1ppCGtGojEoWPngJuPy+2eh/nVKZBsZflPbGSpHv171oLks0kbs6lcrhhjt82OntVeaM+Yx4zuCtxlj9P8RTsCMu6YuwVeMDJV8HHTnIrOuJo0QM0uAB94YFaF4dgWIPhuCZBg4GenFcvq0waB1wXHXCHPfJz+VT1L6GB4i8YQaVJHDb2nn3jjdkyEKqdM/nnH057VY0fVbia4ZbiNoHBG5XBODjOfpnt+NcJ4tlle7ieQRrE5YxRL1A7H1JPfsMV1eggTxC6cTeZOqrgvuVgAOMdODzn3rRpctzHmfNY7G2u5WgEciB2RixO326VfhZZEXAwwGc1Rs7Zo4tivuwMkFsHJHStHa7Jyy7QAmNoOB/d457VCNBl0mVnO1YRtDtg/Kw4/xzVaZxvZPm/drncwBwfX16VYuUMO0NEYwvCJ1DMfT3xx+FUZFkMjx/OV+594tsOccfr9KbERSokSh3zJOiKgUHkAnlT2PXI70k7mzhmNshndSXjiDnMhB9fSnZIlXLgkRtgwsAiD7pI7luwNUAj/YILaFfJjiVQInADIAckIw+bdnGenekK5FczW+mWk1zK72yWwEc87xlixyCNu3gnLDJx3qG8MYvg+5fNWQP58JJeWNVLPHIo+VcM45HJG3NNc3kUGRE2LSEJ+9cOxk9JDxuBypOO/eopmmcRrZiOIx3KtIJQxj2DAbhRwzN2Oeuc0LUTZHcSykSfZ0kumZGjijfakilwANjH5QfV+vp6Vm3EtvGkbLc3EYKiW438pbyEbTEQV3HA46EEkc1ZEQitwkCRLZQRki2ByYt+Nitnnk7iGPPrWJdSLaQzITNmVEY75QzOAwLZB6Ju9udvWhLUEVXYpJeWkW5N0cI2yHJ2gKVRT1XOTnHFSRagwaW2uYxHI1yC0uQcID9wNn2ODz1x6VXiuYmVyYnniWJy0buUX/WZErMvPBbGOe1MuJleWeaGPzVmdJSXIaTaG6A/wAJ9hVWTexSNWLetwFlureRy26NQiucf88jxkMcjPbjqKh3mG0hRrtpGgK7mkQlAcnI29MAkqSeSBxVP7TPd6XLJK2BEz+QYo9pGSo5I7cHk8+9MvZIo5GtYJP3G3y2ZehAPJIBIIyCfxpqNtB7lwmErI1zLceWGVthOSxGBtYjlV6AHrRcXEiQyTKiIzOFw5+7JyB5eMfKFxnPHFUk1ErKXnAufMcbxK5yQMYBPcn/AAqvM5crvO5dpVNwB+XnjPryaOUe25XCLJLuyWwADkk5IrSSG9nsJPKaR7ZZUXyQT80jZAIHTPGKz+EjUKDhegrotThmt/DOnabAjTz3c4uCka5Yk4CKO5z/ADrTbQwvztvoZFw0ttI6zOBIh2ELg44wAfWqc9u5tGlyhQPs+VhnOPT096634tW9pbeOtYjstgCrCZQDkLMUHmKfQg9q5F8SNnAxx/Ki2rQ5O8VI0/Dd2IpIhIpKxsEIBxzzz79q7SOaNVwWbI4JHf3rzO3byr5cHK53kFsAc4zXbWl6sduu0qgbJCk5xzXLV916Gm9mfT7SqQ5YtgdsdfSsy7lYcEfKpP41buWbYVQIz543NgGsa+kkG7GzBOAd2SfWs0ijJ1afC8uqk4Gc/pXLabB/aHxF8PWWCUS4MrgjqFVjn6ZxWzqbnOcDgZB9Ko/CpTdfEu7nO5ksbJ2GTnBcgD+tbx0RjVZtftF6lFaeF9NilBdnujKFB5+UDn9axPhvMdTOu6flRdX9vHeWpflmmhHzqP8AeXp9KpftLm4k1XwxhjHA0Uq/8CyuM1w/g7VrrStTivvMCPaXAMTO2WBX9CO2PQ12RinAyg7anrlpcfaY1L4IBJ9M/UUMMb9y4JySuOB7Ve1S3/tKOHxDocQe3vW23EEZGbec8sgHofvCsqKeN12Mztg5Vf4iPf0x6VzSTTOjToJDyrAbl3AjLcYGMH6UyR9sTNKnyhdxxwWA6Ae/fj1FLIpQqxBZSTkj+70qPBEZUMS6AsrYHU+3bpUgTwSiFNqsA4xtBHGcdSfTk1KrshxEvmIAqmJRgMCSc59TVPaI0afBbgBYwAN/qPSnW52GBxDunxhmboqgfKPTOMdaQ0X0aXMMTyRTRZBLHKsyNnJAHGRkAfSnI+FjigO8bc7nTKKF/vc8Z46VUjkEaQRpmQYKrM3KZAyGOOnJxU6bfkSMJ8riNYg3A4Od3uMnAPtQOxbEmwFicZBByM4XPY+tSqWERkDBo0YAqxJYjpux+VZ8Un7llt1cRYJHdlxxzj73Tp70okKyusKhULYRTIcgnksPXvx700wsauW5RUUR5OCeMt0AGOORz+FMVcpKDIy7AMggZPoR7f8A16rW7M0ymMpBN0EbjhlHJPPAPB4pTdQQW2Y3HlAF8qflPsD/AEqkSRyWpER2khYzhFIwRxzzXP6jY7kzFtToQ46hv8P8a6USoQczOxjJTftDAgevsPUVVniEjPOuGEq/fbgkjuPY1LiNM8w8QeHxcWxWRhAu0hGXkhh0z6DnHHrVfwVb3NnaR2sy7HUsJAv8QLcYPocV6Jd2cU+yRUBR2MUgkXJ3DBwvqOvPtUVvZQr/AKtwy7iEwO464pXtpYXLrdEllG7lGiBwFySSBjBOT7+lS3AVFQsu1ovuRbcFs8nJ9uOaYnlxthllCNydpzkZIqq95IZGdgwBU7nLZ4/uf7P1q9OoEV3IgUyeSEcEr5YJxnvz/eyazpZozk3TCO0yoIibBJDZGB6k9eaSS6mkMZmt7JVjIkQPIRj6sOhzgZ5qvJLEb39zbGS5DsIUuMLnYDvZF6YOcZP1pAOmeabDywJAv3mBbO5yDlg3ZRkdB1rMukNystqZZM/LEZEyJwTgbmY9vlb5sDIxUt28IiQm5iE0fnqk0uEa2jPBKryC2cZY4p19EYYGkkuPtVvDa4eF3/dzzLls7gcgAjBzxyOnNKwihc21o1xLPMssUg3tuEhIR2XlxjPzHd0PoMCgTeaiBbqdCyuh2HbIS3y/MeilSTj6U3z5VsmhhE8Esnlu5LhvOdmUlVl5LNjjdjGBinXl0ktvPdwx5gnG5vLDLtRTtDKAeeRyOM8mgLEEu2O8b7GpmYyQxyojkmTZkBiG49MDvnNc2IhNFMlveQzrFE5V7lXDNg5Kx4Gc+x4AJrYmu7edWV5iloS6zsYxIyFY8JkE5bcyk569BmsS/e1MBkKKX89SIgzIkaheir3O7qaaXcL2K4uWaeeTIgimTy5HVTwcAsq9sbqkE00LpHJGNyHhU4JBGV69Rz355pguDJA0RkSNVHK9FJ9h69vwqO1hxOm10TJHzAfd9/wrWwrkzzSGZ1EhiZ12nbkRkYyPl+vf3qIyEIyJEsO5QroDkEcZ/wAadckySlpD5v8ACshPDKvAwPSoWBC4xwRj/wCtRYHK2iIcBpdhjbygw+VTj8c1KibNwGcFs88kUDCL1woHOTwK63w54WEsUOoa8kqWUv8Ax6WKHbPqDeg7pH6uex4p6LVkOTlojP0bSXkEOoXYEdgCTF5hx55XqB7D1rq/CRRr+PxNfqFsNPkGounOAsXESD3aT9BUcOl3fjPxDJpluLdbS05u5Yfkht4x0jQ9AOOT3ql488RWosG8OeH5vN04OslzcDpI6DCxp/sL+pJrLWUrmt1ThY47ULi41nVLm6uZM3V7cNM7McZZjnmq6Ws0ELs6HYshQyAgqW9M009PrTvMYRCHP7vO/GO/TrW1jBPSxXmbZKhKAr0bjPFdJpdwYLUAReYGO4OHzuHT+mPwrmrr5QjZxtYZ+lamkakIrQxu6gKx2g46fiPrWFZPob09Yn1zcyLsAzuB6kjgisK+k+8o28dWNbF60bAgDjOSAfyrn9TBLkAAnPQdDXOizmdcdGBJIkXrg1e+BCeZq3iq98xnC+XbbmHB/ix+orF1+TZHszjJOAOgPrXTfAOMW3hbWtRnI8iW+Zyx7IigH+VdCWxzVWcf+0PqRvfE1vpVuSJtPtvPVh13N1H5CvKbxY1srFDhrmV1d05AOT1PvkVsfEzU21Xxxqd+XUBv9XySdu3274rmbOSK2kga4QSw8FFAOV5zu+tehTVo6kxPT/BniW700xWs8ipHJ6vhc4wD9R2Neu6ro6alp0GraXMkk8qAmTGxLgjgq39yceh4bjFfMds/9oaxEbNQsDZklWV9u0L1P04r1fwH4yvNJ08i6tmvNGuGZJVkPzbRxtcD0xlXHI96zq0rlqpZWZuyv8rxnMci/K6MCpB77hUBcs4DfNlsAA4yeuAfpXZzWOleMNIOpaNeIbkbQl1KfmwekU4HUdhIPxrir2K50/UJbPVIXt7uJgdjdOnVT3GO9cji0aXuPAklmWANlipZDjoex59/5U1XkRJTcyyyxpEvmhlAjP8Aeb3J7Cq7sMklipJ+f5s+2M+n8qkLgShdqSPkbVDYGMkdexA7e9TYq5allZJXQgyXAOWTeQpOBgE9Dn17U4OVeSQ/MpIeXy4/nLEHP+983SqpkneN0eUZjiLB2cLj/pmeOT6UlxORazXEKXTstsjqV+QTKzcGM88gZJ46UrFXLokt/tAaZXhKyBRI2cBmHGGHXHcVJHcNDuUou9lJMpyQ5zg5A7iqkU8EtwBbSNJkcxhC+3gZBHQOOOeelQpPE1vIiusg3skpIMYWUdWz78UIDW3ORKDGBK6kBnyQyehz0zTTMnlHylSZQodNiAg+g9VJ9/SqM0ixRBXlTEjHypGXBIGDjH9fWmTOJEkZGjhO9fMycHaf4xt4yT3pgXLp3SRmMEkjhsusBwFXuC3fHH51WnnVSozmZm+d5E2iQAdE/DjNQecJGDSSYlY7o2jlP7zHG5vTjj6mke5nl8qOPyp1w23zOfLB5bHuSBn6U7kllJJHjJaMPhTwpwqjsM/nSSyTKpDYBMgfdn5d23pj1xVP7YrXXkxv823cbdVLH2JOcfQfSoZLsIrxxSEyIC0m5A7AgdRnvg44oAsTXAO0vInmEEom8qqsOmfbrWbMww5tmBH32aNTgZHcdQKjlvHuI2jjl8yB9qRqUDMZDnI5wOBjH1NUr2eKzLx3M81qvmbWktkDCRjkbG5y55Ix269qGST3c3lKkbtDCJB/o6fxzOBlm2d1wRjP+FNgmEIEyHcfL2yEyk+avBAz02gjms2WQxsshaN5IuZbiaM7Mcny0fP0JI9qSa6ENrKbycGNF2bYpCELsRlkUfe+bAx9TUjLIby4At1PE8MkIaf90C1xtJyznH+rAIwD6GqF08bM3laaWiaNkaaIksQ5LONo6KQEyTwMmpsSwC6aSGWERNmQQBWLo5HG09OcgDPAOabKzfbBEXCHO50f/ll0UZ5+fLE5PQU1a5JR1CfyE+zzXEiLCI5pJHG9kiyAoyuB94444AxVXU5AYZoTJcwtGInnbOGLuPkGBySF5IA5xUVpqlnHDDHcxzx2oLkiTOQrdXded4J4CnpjNZzXjJdpdwxkPKEEe1SzJj/VM2eN3A/DNUoj1LU91FJcXcsUdveyRKVgknUsLs4EbybeCoIGV7jHY9M++uftEod5mk+VQV6bNqgY6e2OKR9yRW6SLuuctudBgOCSePfcTULKYywYjkdjnr2PvWiVjOTuSgxHykeFo0DfOwA3spOc/XFF2sSTyC2LeQTmPcQWx7471AWZyMksQAvPXjpUrQkWhuC8IjD7NvmDfn129ce9URe4vnv9maALH5Zk8wnyxvzgDG7GdvHTpmpdL06/1i9Sz0q0nu7liPkiXO0E9WPRR7niug0PwdJdxwXOtzyabbTbTbwLFvur0EZHlx9lxj5j616gmjaZ4X0wprH/ABJ9GdQp02GYvc3xweZpOpJyfkXAGcUm+xcYN6s4rw74HDqsyCG+uEx51xMR9hsiGznP/LU4GOOM1c1Bxq1xdR6Zq7rpkQP9reJrlvnkXHzQwnqRjgKvt+Nbxf4tTULdbSf/AEDQEby00e1wJZQP+ehH3B0+tcDqmrXmpQW9vcOFsrYEW9rGMRxAnPA7n3PNSk5asuUlDRf16nQ+JPE9u2hLoXhZhY6HHJ8yBWWa84HzyH046VxgGAABgU6ir2MW29WJ60/BIJ6HsP730pnerOnQxyahEku8b/kUr/e7UnsEUm7MheUC3MTojITvwV5J9M1TtfLjjImj+bOee1X2t5Rcm2CMZw2zYvJLe1ULuNVlw+RIBhg3UH35pS1Naba0Psa9kwH3EBUGSdvPHtXO6hJyhAAJPy54JrcuZFRsFjk9Nwx07CuZ1Qjdk8qxxkt0rjibHF+L7lIo3keQhY1LMO4J6fmauaT4lis/hXpmh2FzFJe3ayXF7Ih4jTefl/3ulYPj+8SKwYlTKH+X5egHTJrA8ECFbK8LPmQ8FPbsf5120Y3ZyVDl9WmWS6nlj5V5flJP5VGsyw2UjQRqkzrsdXzuJ3A7wew7Yqe+iEF1cRHO1CcZGOKqbHkR3lZgGBkBUZCnHGcc812UkruLJvodl4Ztprq0tgwEZs0ljjxgrMsnJDH2PY1ciuL7TmeZpv8ARgmC4G/djnZt7jHSpNDZZNAsIrUpHMsY3qwAySfmJ9zWVrerfZ9R+yWnMFv8rYGTJJ357exobUSd2bug+Mr3Q9bzplvJEJI91xEhGUBAO0A8E/3h3z7V65Hruh+L9AMl3DKYrVAsrwLmaxP99O4j9Yzn2r5hlneKaO4M5jn8zGQCSuf4umPwrd0vxbdaRri32n3D2tyr/u5UHyhQMFWU/ez6H1qHS543RpGTTses61pVzpHkvNJBdaddDNrqUBzDcD+6fRh0INRhpPNiljZSoYoxC55xz/n6Vq+EfFOja3EI7ZrPSL69B+1aPfn/AIl18T3jbnyXPb0J70us+GLqOe4XRobtJIk3SaRcAC4hXON0TdJouwZST0rjlBo1TXQw9yJEStpI3nEDC4GD0VWB6n0PvSpKbi6kRZJDeI27EQ2NFwCQrchv7px2JFVWuIzGRB+9CAnDdS2PukdueeaLmWKeDyLyN54njYMckMyjqvHI79OozWTNEy81yixeZNdy7TtZ3hXaVJfAIwMgYwp9gaejSKhFw6zn+NVICeWD8r5xy3/1qzpXZYisd00fnxlIJ413PbkL0CkfdPHynrjtSPKJIbd5oEn8vbwFCL8ygF8k/KpPOB+VIq5eke6SSfzJ4HjyHUGHcY4wG3L7Maa0jyLDsadFxujKyDaPoOrKepHSqF04lU+XctBiZSJI8BlOCepGGX2plxqHmsJEieNGGW82MiRV9ueMYOcCmhF17uNpibm+W6C4BVXAZsj7524IYn86rXE0ezYt1chQcA72BY44AB5OOfyyOlVDeMxlQTOYnTIRgCisO5OM/wCfeq0txHLM+9jKUUjOCu/pjn+7k45P0p3uK5bN4mQpEp2DMrEkEMeQSvUk4zgH0qtPKZLHd9pUQ3LKqysoTecjAVTg/wCFZrXUsihTI5ZifLVGV1U9CAR39TUTXiyTO/mI8hXaGfO4t06YzQK5dvrgTSSq9xb2lzEu6TzR8qx7iNozgYIAyeT1qAyQ2kEkkcRgiYNHtwfmBwMpjlsbh83bmqVxczmwBj8q5RVLNEyeaBg4JWMfe5ByCeO9RxyJHKWtnlLyBY/JdlUQjbnhR3I7DjAOTQloK5eTfcILXMs07kwwCLBSUgAthT94diOKpxzNDKZIN1pDbkBdpWJY0PBbc2Q2eTgc1BMYXMc0qxsuzaMOxMmCWQFRwoxzn2pAjGGWOeESxlI1jl+RizAlirKDhc8Y7YHXnFCTsFyHGjpKBNYs9kzi7nt4pWeSUDKo7PznJYkp1FLqD3aT3D3919p1GM/JcRICqE4H3iOTgEDH92mf2jHBfQLL5t5bRxqrwxqCrbd2BvHYbvmI59Caq5aGyupvthvEj+QSSK20uwBCqG+bqDz04rRCGWlzPLI0kg+0KwXaZlMjEqSSykn5iuT3x61DamJZWlt3WeBAwbzJdjNkEA468egps8qzWyPG8ikSOFhL8RoQOg6DuOKdPePdTSTXYDylQqlEWMKQABwBjGBjAqkTNorF2YIXcsyoFBJ6AdBTc+lXtG03UNZm+x6RZzXkzEBvLTKpz1Z+ijnnJrv/AA18PYmmY3KRa1OnytHFIY7KBsdXm/jI7quapuxCi5bHE+HPDup+IvObTYkWzt+bi+nby7eAerue/sOa9Q8K+BLSCBLzSYxNIq7zrupxgQx4PD28J6n/AGm9MiuunsbHRtPivfED2siQ8xLMBbWcOecRRfx9TyQSa4HxN8ULU7o9Mik1a5U/Jc3abLaI+qQ/xY9WqXdlpKJ0kniHTNGhmm0J1u7mbKTa/qj5jBHVUJ5bGOETivKvFfiQahfztb3dxqQePyzfXq4diD96Jf8Almp9OtY+r6zf6y27VZ/tU4curtxtz2CjCgfQVm/jQo9xSqPoKxJJZiST1JOSaT6dKWiqMwooooAKVHaN1dDh1OVPoaSkoAfLLJNLJNKxMjNkt6n1qjd7PNG4/NjnNW+lIUDHJFFik9bn1bqVwFYnIHGBkZx75rnNTkLEbyFA4PNbuoznzSrFgAM+w/zxXKai3yy5IUgElieScVwxWp1vY4Dxmk15KLRNuXlAEmf4R14rmtEv2tNRnRbUSWlsrCfe+xuvDA9A3QAV0d6WuY1ulkVZCTtG7nHTH9PxrEsUjvNYlQRJFC+TJGqFQG+h6445r1qMOWNzgk7s0dTs4L/SRJa3IlZiWWV1wx9m+lcfcpNCyfejKDJ6jK9CR7V0Fg39nX32G/Ijt5G3o5OfL64b6npzVrVdO+0oqxW/2i2XlhnDRtjrknlTVxs3fqK9jH0eWa7t2vLaKQPZcZ3ZDKQePdvQ1Qi3PhslZGBbPcEir9ppc8twY0cxRtH5m5XKjg4IYd+/5VRnga2uZYZHYv1znkg8Aj2pVejGisCbfapSRIz1IOTuJxg5okjgE6yB5FkYbiMHnnoarkCK5WNpX8nq+49f/r1Os8zzvHEiGPdwychcjgE98f0ro5YyV11GvMs/bZLeAx5/fK275j95Oy49Rk16H4H+LOp6VZLbam41nTIQNttdE74cH70cv3kODgYOBXm1wZIS7qMIrKx3dWGP61HHKqXG+RVQrxuHIBPbHpWcqd/iQXPp+yvfCfxLCS6PqSabqbjmG72xzyv2Xd92UHpzz71yGrwXOhaiNO160ewuwu3cynYyj+JW6H8DXiYUqEA3yRtjGDgHnjmvQPCfxT8ReH7OPT7ww63pOVU2epL56IB3Un5gfxx7VyTpLoylJo6FP3u4ht642ptI9ex6g1XefaSZyr7DzlcBz2GP4sdCa2ItW8B+LTPbtLJ4P1tmDQzq/m2jcH5S+PlBJy2emK57xFofinw1IJL2O3/s10It9Rs83FvcDoMsudpxzlsVg6TRaqE+Y4FU5+ZG8pkWUZJY9MGmTCcxSBJPNXI8weZjOM9G7EeneukXwTc30Vs3hXxN4a1hXiUqhuBBcIcdNpz1561l6v4J8a2nyz+E724CNhGtXW4UD1+U5x/jUum1uP2iZiTyjzgAhUDGxct8w9cHoO2aovKBIvQxHdgM24D04747VW1a5vtOBXUtK1OB2AAjntZEwOzZx0z/AC6VgtrW5XKoVkJ4OOeOm7jHHP50KFw5joZbiKQkKi8YB2KSz++ffByR1xVa4meNCqnLwsDt35kZmO1SSeFGOeMdetYml6frWpIBotnqF4Y51w9rCXZG7Jkdc+h9K2rTwN4z1CCOS18N6y+3cm82/lqQDzluMtuz1/CnyBzJCXE5s7fnZAyDJVPm35ONzDr1B/3s5FT29uu9pre6RYYEMjnyyIvmGAq4GSTk4JPt3om8B+Ore1klm8N3MeMKHZEDIMdFGc9KZceFPFCqFk0WaIOu7YXGDjPVcnIxS5Rp32K11dFruQs8cLlfNVFXY7AKAMYPOc9D6VRkuJr1ngW4zghQ2/yyQwJOR3PGM5rTj8F+K7/y7O10WSYBd6w2y7tvXnPX14J71v6X8IfFl/asJ7Ka0TaGKXKeV3P8R4yPT3qkkPVHnyxEktIiuzqxEfTzG9foMdu4pnnYUedIA7gZLHLHFes/8K18P6Ig/wCEr8X6dby7QRCt4rSp7qEydv4VOPEHw48PArpKy3zcbnsrPazMP7zT54/3QKqxLfmcHoXhXXPEmyaztI4LXGPtdziCAAdfmOMmuz8PfDi13Ca7a61po/nP2f8A0axCg9WmcZceoWqmq/Fu5YZ0HRLawmPW6uZDdShv7y78qv0xXB63r2ra7K0msaldXhZt5SRzsBxjIQfKPwFVqZ3SPYb3xN4V0G3jsby9iurUAEaXoaf6Nt6DdIf9a2BzuPPpXNa/8Wr2cCDw7YxaZbRnEbOA7hewAxtA9sV5iFCjAAH0FFGwNtlvU9RvtWunutVvLi8uW6vPIW49AOw9hVQUtJQIWiiigAooooAKKKKAEpaKKAD0pCOaWigD6Zv5Sz7nKF26ADOPY1ymtTNJbzJuj+YFRk8kY5B9K39Vco5x1U8GuC8YyuNKmdiCAu7aOMsR14rjpo66mxhWMg/sK0kwN3zdCVHBI6ms3w5LIrtu3spbCBm5BHUc84zWxH5kOl2aI/zeTkNjpnnp9ay9Ot40hnI3lygbczE85969iPwnAy3rVst/p7ToA1wvy7S2MYNYtldXRkjhR/LuUBRDJ909SAw/TJ9a6CF9pmBG4blJDcgnHWsbXLSP7K94uVeMhducj7wH9aVuqBPoM0/WJbqzuLKOT7JOQJHlkbBDj/2Q88dc1m3DyrcXH21Y3l8pSJU55OOPc/yqI3c9q5uYnXeWCvvQNvye+fpWjDPHrMlv9pt0hlaQkvanyx90nleR2qr88b9yrWMWeJ5mBRQQoPOzdx6fX2qKSOZVGxJHCr8owBtB54HqKtmJpNPdmfkuqkgYPI9apY8mQzjGImU7BnB5+vHSrUZQsrgNuAZb2KPLjIAy5ywB7H6VIWe2BmaPe7qYySwOB0GB+FLIFkildlz8hOM9+e/ekSARRs6s3zQ/MCetJVLLUYxTAI9qmcgjC84wfUfjVsTxCPDTKXPIwpwBjoT6+9UQWOnROrFXjkwpB5Hfj8aiS5IjERRSM8nuQe39a05Yz3QtjQS5V9oKSLu4GRwfxrZ0rxFq+lWzwaTqc1vCxZXQNuRs9QVPBrLtVLjytxUHgEdRkVJYWoWzlkEsgeJt3XhgeCCP61xuK1a0Gzrf+El0PU3jGv8Ah42rhfnudFm8gu3GMxkbema7Tw/ZaDqNureDPiZqGh3o4az1XfEoPYGRSFP6142Of5UjorrhhkVm5DPoPXNT+MHgm1jmvLq21rSGw32i3jW4T8cjdXJL8bdS3t5ngzwtO0jYkJshl/c85z+Fcj4J8ca94M1AXOiX0kaNxJbud0Ug91PH49apeINbk1XxJLrUUEVndTP5xWH7que6jt9KLrrqI9CPxiZ2dF8HaLCHO+U2Ze3LsvQjbjBHr1qjL8StFkvBJN4OmaFVAiii1u4jXccl2YA8kk15pPMzDdIS7M+SSe56mmEAMoKg7TkZ7UaLdDPT1+LS2UZj0Twdo1sm7Ob2R718f7znNVm+MniyNkOnR6Jp2wFUNrpyKUU9hnPFec5zRU6dh3Z2WpfFDxxqKlbnxJdhc5/cYhx/3xiubvtY1XUEMd/q2o3UZJJSe5dxn8TVClouIRQMevpk5paKKQBRSUtABRSUvegAooo70AFFJS0AJS0UlABS0UUAFJS0UAFFFJQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with ichthyosis vulgaris has truncal involvement. The appearance resembles fine fish scales.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George A Datto, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8645=[""].join("\n");
var outline_f8_28_8645=null;
var title_f8_28_8646="Binge-eating disorder: Cognitive-behavioral therapy (CBT)";
var content_f8_28_8646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Binge-eating disorder: Cognitive-behavioral therapy (CBT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Robyn Sysko, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Michael Devlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8646/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/28/8646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H368103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binge-eating disorder (BED) is more prevalent in the United States than either anorexia nervosa or bulimia nervosa. In a large, nationally representative community survey in the United States, the estimated lifetime prevalence of binge-eating disorder (BED) among women was 3.5 percent and among men 2.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, BED is associated with numerous psychiatric and nonpsychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Most patients report some degree of impairment in psychosocial functioning (home, work, personal life, or social life), and 19 percent report severe impairment.",
"   </p>",
"   <p>",
"    The course of illness appears to be chronic among many patients presenting for treatment. The mean lifetime duration of BED in one study was 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many treatment options for BED, including psychotherapy, behavioral weight loss therapy, and pharmacotherapy. Psychotherapy is considered the treatment of choice for BED. Among the different psychotherapy options that are available, we suggest cognitive-behavioral therapy (CBT). &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    This topic describes use of CBT to treat BED. An overview of the epidemiology, definition, evaluation, and treatment of BED is discussed separately, as are anorexia nervosa, bulimia nervosa, and obesity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link\">",
"       \"Binge-eating disorder: Overview of treatment in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368152\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy is first-line treatment for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Specific psychotherapies that have demonstrated efficacy for treating binge-eating disorder (BED) include CBT, interpersonal therapy, and dialectical behavior therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H130122373#H130122373\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The psychotherapy of choice for BED is either CBT or interpersonal therapy, based upon the results of randomized trials that have evaluated each treatment, either separately or within the same study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. We suggest cognitive-behavioral therapy because it has more evidence supporting its use. In addition, CBT has the advantage that it has been adapted for different formats, including therapist-led (individual or group) and self-help. (See",
"    <a class=\"local\" href=\"#H368166\">",
"     'Format'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180128041\">",
"    <span class=\"h2\">",
"     Theoretical foundation of CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard CBT used for BED is adapted from the type of CBT that was developed for bulimia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/14\">",
"     14",
"    </a>",
"    ]. The CBT model for BED emphasizes the critical role of both cognitive and behavioral factors in maintaining binge eating behaviors, and focuses upon regulating food intake and reducing episodes of binge eating. The core psychopathology among patients with BED is they over-evaluate (over-value) body shape and weight, meaning that self-worth is largely or exclusively dependent upon shape and weight, and one&rsquo;s ability to control them [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/15\">",
"     15",
"    </a>",
"    ]. This produces dysfunctional eating and dieting behaviors, which lead to a psychological and physiological vulnerability to binge eating episodes. The recurring binge eating causes distress and low self-esteem, which lead to continued dietary restraint (attempts to limit eating) and binge eating [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180127852\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reviews and treatment guidelines concur that CBT is a first-line treatment for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. CBT is indicated for patients who are willing to engage in the therapy and perform the work required by CBT, or at least sufficiently motivated to begin the process as motivation can be addressed in the course of treatment. Goals for treatment may include reducing the patient&rsquo;s:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Binge eating episodes",
"     </li>",
"     <li>",
"      Psychiatric comorbidity such as anxiety, depression, or substance use disorder",
"     </li>",
"     <li>",
"      Concerns with body image (ie, enhancing self-acceptance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weight loss for overweight or obese patients with BED is not a suitable goal because CBT is ineffective for weight reduction in this population.",
"   </p>",
"   <p>",
"    It is not known whether there are different subtypes of the disorder that respond preferentially to CBT. There are no specific contraindications to CBT. However, as with all psychotherapies, the patient must have the necessary motivation and interest, cognitive capacity, emotional stability, and energy to participate in treatment and complete assigned tasks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180128091\">",
"    <span class=\"h1\">",
"     DELIVERING CBT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368166\">",
"    <span class=\"h2\">",
"     Format",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is usually administered by a clinician (therapist-led) to either an individual patient or a group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/8\">",
"     8",
"    </a>",
"    ]. A course of treatment typically consists of 20 sessions, each 50 minutes in length, occurring over four to five months. Alternatively, patients with BED can receive CBT through a self-help program, which requires either limited or no involvement of a clinician (guided or pure self-help). (See",
"    <a class=\"local\" href=\"#H180128374\">",
"     'Self-help forms of CBT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368180\">",
"    <span class=\"h2\">",
"     Therapeutic techniques and procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several specific interventions are included in CBT for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinicians should direct and help the patient to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understand that binge eating does not occur spontaneously. Rather, it may occur when the patient:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Breaks his or her dietary rule system, established prior to the onset of treatment, and reacts with dietary restraint (attempts to limit eating) and binge eating",
"     </li>",
"     <li>",
"      Ingests alcohol or another disinhibiting substance",
"     </li>",
"     <li>",
"      Under-eats, which creates psychological and physiological pressure to eat",
"     </li>",
"     <li>",
"      Encounters an adverse event or becomes dysphoric",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor eating behavior, which includes using a diary each day to record in real-time each meal, snack, binge episode, and the context for the eating situations (",
"      <a class=\"graphic graphic_table graphicRef67548 \" href=\"UTD.htm?32/19/33085\">",
"       table 1",
"      </a>",
"      ). The patient should discuss the entries in the diary with the clinician at the next session and look for patterns and common antecedents to problems. As an example, binge eating episodes may occur every time the patient watches television, or after an argument with a significant other.",
"     </li>",
"     <li>",
"      Develop a regular pattern of eating (eg, three planned meals and two to three planned snacks per day) with no more than four hours elapsing between eating episodes. It may be necessary to gradually implement the regular pattern over a few weeks.",
"     </li>",
"     <li>",
"      Recognize high risk situations for binge eating and learn coping skills such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alternative activities that are incompatible with eating",
"     </li>",
"     <li>",
"      Learning to recognize that the urge to eat is temporary",
"     </li>",
"     <li>",
"      Stimulus control (avoiding people, places, and activities that trigger binge eating)",
"     </li>",
"     <li>",
"      Problem-solving (identify the problem early, specify the problem accurately, generate multiple solutions, think through the consequences of each solution, choose one solution, and act upon it)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modify dieting behavior, ie, avoid prolonged periods of time without eating",
"     </li>",
"     <li>",
"      Address food avoidance:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identify those foods that the patient regards as forbidden because of the belief that they will inevitably lead to binge eating",
"     </li>",
"     <li>",
"      Help the patient disconfirm this belief by introducing a small amount of the food into a planned meal or snack on a day when the patient feels in control of their eating and capable of resisting the urge to binge eat",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Address and restructure dysfunctional thoughts (cognitive distortions) about body shape and weight, eg, by discussing their importance relative to other areas of life, including family, work, friends, and recreational activities. The clinician should focus upon the patient&rsquo;s over-evaluation of shape and weight, and encourage the patient to actively engage in other areas of life. At the same time, clinicians should validate the patient&rsquo;s legitimate concerns that obesity may interfere with other aspects of life.",
"     </li>",
"     <li>",
"      Weigh her- or himself once per week, to address unusual weighing practices (either excessive weight checking or avoidance of weighing). The clinician should educate the patient about weight, weight changes, and body mass index and its importance to health. &nbsp;",
"     </li>",
"     <li>",
"      Prevent relapse after finishing acute treatment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Review the patient&rsquo;s progress and identify continuing problems",
"     </li>",
"     <li>",
"      Educate the patient how relapse generally begins with a single event that escalates, eg, the patient may respond to a critical comment by resuming dietary restraint (attempts to limit eating), which may then lead to an episode of binge eating, followed by further attempts to limit eating and additional episodes of binge eating",
"     </li>",
"     <li>",
"      Develop a plan that the patient will follow if problems occur, including the possibility of resuming treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonadherence with treatment, including missed appointments or failing to complete homework assignments, are addressed directly by the clinician and attempts are made to engage the patient with treatment and the need for change [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An enhanced form of CBT for all eating disorders, including BED, has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/16\">",
"     16",
"    </a>",
"    ]. This treatment includes additional methods for addressing dysfunctional concerns about body weight and shape, as well as modules that address problems that maintain or reinforce binge eating (eg, low self-esteem, perfectionism, and interpersonal functioning).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180128374\">",
"    <span class=\"h3\">",
"     Self-help forms of CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BED can receive CBT through a self-help program using a workbook that requires either limited or no involvement of a clinician (guided or pure self-help based upon CBT). Practice guidelines indicate that self-help programs are a reasonable alternative to therapist-led CBT, as a first-line treatment for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors limit the number of clinicians available to provide CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/17\">",
"     17",
"    </a>",
"    ]. Clinicians who are well-trained and experienced in CBT are in short supply. In addition, the treatment is time consuming, and patients with limited financial resources usually cannot access CBT. Self-help programs were thus developed to make CBT techniques more available to patients with BED.",
"   </p>",
"   <p>",
"    The workbook (either hard copy or CD-ROM) used in a self-help program [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Educates the patient about BED",
"     </li>",
"     <li>",
"      Outlines the cognitive-behavioral model of BED",
"     </li>",
"     <li>",
"      Provides a step-by-step program",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For guided self-help based upon CBT, several workbooks are available commercially [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. We suggest the workbook entitled, &ldquo;Overcoming Binge Eating&rdquo; because it has been the most studied and longest used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. As in therapist-led CBT, the program focuses upon developing a regular pattern of moderate eating by monitoring oneself while eating, learning techniques for self-control, and learning how to solve problems more effectively. In addition, maintenance of behavioral change is emphasized to prevent relapse of binge eating.",
"   </p>",
"   <p>",
"    Clinicians who have some familiarity with eating disorders can guide self-help treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. The clinician meets with the patient approximately 10 times, with each session lasting about 25 minutes. The clinician provides a rationale for using the workbook, encouragement, motivation, feedback about the patient&rsquo;s progress, and assistance in applying the concepts described in the book.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122507955\">",
"    <span class=\"h2\">",
"     Nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be reconsidered for patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do not engage in treatment despite repeated efforts upon the part of the clinician",
"     </li>",
"     <li>",
"      Make little or no progress after 10 sessions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In either situation, the patient&rsquo;s overall motivation should be assessed and alternative treatments considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368187\">",
"    <span class=\"h2\">",
"     Ending treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should end after the planned number of sessions, provided the patient has made progress [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/15\">",
"     15",
"    </a>",
"    ]. It is acceptable to end treatment if the patient still has some unhealthy eating habits, occasional binge eating episodes, and some excessive concerns about body shape and weight. However, clinicians should consider continuing treatment beyond the initially prescribed number of treatments or switching to an alternative form of treatment if the patient&rsquo;s binge eating interferes significantly with functioning and the patient is unlikely to manage these episodes independently.",
"   </p>",
"   <p>",
"    No studies have examined whether continuation or maintenance treatment with CBT is beneficial in preventing relapse or recurrence of binge eating in patients who have recovered from BED. In practice, clinicians sometimes schedule one or more follow-up visits at intervals of a month or more to monitor post-treatment course and resume treatments in the event of relapse. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368194\">",
"    <span class=\"h1\">",
"     EVIDENCE FOR EFFICACY OF CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT has been more widely studied than any other treatment for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Randomized trials of CBT have found that remission from BED, with abstinence from binge eating, occurs in approximately 50 to 70 percent of patients, which is maintained at one- and two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, CBT is associated with excellent rates of treatment completion (approximately 80 percent) and with reductions in depressive symptoms. Treatment guidelines concur that CBT is the treatment of choice for BED [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H3058077#H3058077\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Cognitive-behavior therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid response to CBT, ie, a fast and clinically-meaningful change in symptoms, is associated with a good prognosis for patients with BED. In a randomized trial, rapid response was defined as a 65 percent reduction in binge eating by the fourth week of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with a rapid response to CBT were significantly more likely to remit from binge eating compared with patients without a rapid response (73 percent versus 43 percent).",
"   </p>",
"   <p>",
"    Although BED tends to follow a long-term remitting and relapsing course, nearly all treatment studies were short term. Some of these studies have collected follow-up data one to two years after the end of treatment, but there is limited information describing the status of patients more than two years after treatment ended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368285\">",
"    <span class=\"h1\">",
"     COMBINING CBT AND PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials concluded that in general, augmenting CBT (the treatment of choice for BED) with pharmacotherapy does not reduce binge eating significantly more than CBT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8646/abstract/22\">",
"     22",
"    </a>",
"    ]. Combining CBT with pharmacotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H103239749#H103239749\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Combining CBT and pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of pharmacotherapy as a sole intervention for BED is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H3060670#H3060670\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Pharmacotherapy'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368334\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive-behavioral therapy (CBT) is indicated for patients with BED whose goals for treatment include reducing the frequency of binge eating episodes, and addressing concerns with body image and psychiatric comorbidity. CBT is not indicated for weight loss. (See",
"      <a class=\"local\" href=\"#H180127852\">",
"       'Indications for CBT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT is usually provided by a clinician to either an individual patient or a group. A course of treatment typically consists of 20 sessions, each one 50 minutes, occurring over four to five months. Alternatively, patients with BED can receive CBT through a self-help program that uses a workbook, which requires either limited or no involvement of a clinician (guided or pure self-help). (See",
"      <a class=\"local\" href=\"#H368166\">",
"       'Format'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several specific interventions are included in CBT for BED: understand that binge eating does not occur spontaneously, monitor eating behavior, develop a regular pattern of eating, recognize high risk situations for binge eating and learn coping skills, modify dieting behavior, address food avoidance, address dysfunctional concerns (cognitive distortions) about body shape and weight, and relapse prevention. (See",
"      <a class=\"local\" href=\"#H368180\">",
"       'Therapeutic techniques and procedures'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Self-help CBT workbooks educate the patient about BED, outline the cognitive-behavioral model of BED, and provide a step-by-step program. (See",
"      <a class=\"local\" href=\"#H180128374\">",
"       'Self-help forms of CBT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should end in most cases after the planned number of sessions. It is acceptable to end treatment if the patient still has some unhealthy eating habits, occasional binge eating episodes, and some excessive concerns about body shape and weight. However, clinicians should consider continuing treatment beyond the initially prescribed number of treatments or switching to a different form of treatment if the patient&rsquo;s binge eating interferes significantly with functioning. (See",
"      <a class=\"local\" href=\"#H368187\">",
"       'Ending treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/1\">",
"      Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, et al. Medical complications of eating disorders. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/3\">",
"      Pope HG Jr, Lalonde JK, Pindyck LJ, et al. Binge eating disorder: a stable syndrome. Am J Psychiatry 2006; 163:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/4\">",
"      Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol 2007; 62:199.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Eating disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline 9. file://www.nice.org.uk/CG009 (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/6\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/7\">",
"      Vocks S, Tuschen-Caffier B, Pietrowsky R, et al. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord 2010; 43:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/8\">",
"      Wilfley DE, Agras WS, Telch CF, et al. Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: a controlled comparison. J Consult Clin Psychol 1993; 61:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/9\">",
"      Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry 2010; 67:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/10\">",
"      Wilfley DE, Welch RR, Stein RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry 2002; 59:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/11\">",
"      Sysko R, Hildebrandt T, Wilson GT, et al. Heterogeneity moderates treatment response among patients with binge eating disorder. J Consult Clin Psychol 2010; 78:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/12\">",
"      Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005; 13:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/13\">",
"      Grilo CM, Masheb RM. A randomized controlled comparison of guided self-help cognitive behavioral therapy and behavioral weight loss for binge eating disorder. Behav Res Ther 2005; 43:1509.",
"     </a>",
"    </li>",
"    <li>",
"     Fairburn, CG, Marcus, MD, Wilson, GT. Cognitive-behavioral therapy for binge eating and bulimia nervosa: A comprehensive treatment manual. In: Binge eating: Nature, assessment and treatment, Fairburn, CG, Wilson, GT (Eds), Guilford Press, New York 1993. p.361.",
"    </li>",
"    <li>",
"     Cooper, Z, Fairburn, CG. Cognitive behavior therapy for bulimia nervosa. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.243.",
"    </li>",
"    <li>",
"     Fairburn, CG. Cognitive behavior therapy and eating disorders, Guilford Press, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/17\">",
"      Sysko R, Walsh BT. A critical evaluation of the efficacy of self-help interventions for the treatment of bulimia nervosa and binge-eating disorder. Int J Eat Disord 2008; 41:97.",
"     </a>",
"    </li>",
"    <li>",
"     Fairburn, CG. Overcoming Binge Eating, The Guilford Press, New York 1995.",
"    </li>",
"    <li>",
"     Agras, WS, Apple, RF. Overcoming Eating Disorders: A Cognitive-Behavioral Treatment for Bulimia Nervosa and Binge-Eating Disorder, Oxford University Press, New York 1997.",
"    </li>",
"    <li>",
"     Schmidt, U, Treasure, J. Getting Better Bit(e) by Bit(e): A Survival Kit for Sufferers of Bulimia Nervosa and Binge Eating Disorder, Psychology Press, East Sussex, UK 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/21\">",
"      Grilo CM, Masheb RM, Wilson GT. Rapid response to treatment for binge eating disorder. J Consult Clin Psychol 2006; 74:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8646/abstract/22\">",
"      Reas DL, Grilo CM. Review and Meta-analysis of Pharmacotherapy for Binge-eating Disorder. Obesity (Silver Spring) 2008.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15601 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8646=[""].join("\n");
var outline_f8_28_8646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H368334\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368152\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180128041\">",
"      Theoretical foundation of CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180127852\">",
"      INDICATIONS FOR CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180128091\">",
"      DELIVERING CBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368166\">",
"      Format",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368180\">",
"      Therapeutic techniques and procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H180128374\">",
"      - Self-help forms of CBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122507955\">",
"      Nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368187\">",
"      Ending treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368194\">",
"      EVIDENCE FOR EFFICACY OF CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368285\">",
"      COMBINING CBT AND PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368334\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/19/33085\" title=\"table 1\">",
"      Food records standard",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=related_link\">",
"      Binge-eating disorder: Overview of treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_28_8647="Sulfasalazine: Drug information";
var content_f8_28_8647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfasalazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12677?source=see_link\">",
"    see \"Sulfasalazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"    see \"Sulfasalazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azulfidine EN-tabs&reg;;",
"     </li>",
"     <li>",
"      Azulfidine&reg;;",
"     </li>",
"     <li>",
"      Sulfazine;",
"     </li>",
"     <li>",
"      Sulfazine EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulfasalazine&reg;;",
"     </li>",
"     <li>",
"      PMS-Sulfasalazine;",
"     </li>",
"     <li>",
"      Salazopyrin En-Tabs&reg;;",
"     </li>",
"     <li>",
"      Salazopyrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5-Aminosalicylic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Enteric coated tablet: Initial: 0.5-1 g daily; increase weekly to maintenance dose of 2 g daily in 2 divided doses; maximum: 3 g daily (if response to 2 g daily is inadequate after 12 weeks of treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 3-4 g daily in evenly divided doses at &le;8-hour intervals; may initiate therapy with 1-2 g daily to reduce GI intolerance.",
"     <b>",
"      Note:",
"     </b>",
"     American College of Gastroenterology guideline recommendations: Titrate to 4-6 g daily in 4 divided doses (Kornbluth, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 2 g daily in evenly divided doses at &le;8-hour intervals; if GI intolerance occurs reduce dosage by 50% and gradually increase to target dose after several days. If GI intolerance persists, stop drug for 5-7 days and reintroduce at a lower daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Crohn&rsquo;s disease, active mild/moderate, ileocolonic or colonic disease (unlabeled use):",
"     </b>",
"     Oral: 3-6 g daily in divided doses (Lichtenstein, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Desensitization regimen:",
"     </i>",
"     For patients who may be sensitive to treatment, it is suggested to start with a total dose of 50-250 mg daily and double it every 4-7 days until the desired dose is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Enteric coated tablet: Initial: 500 mg daily; increase dose weekly by 500 mg (total daily dose given in 2 divided doses) to maintenance dose of 1 g twice daily; if inadequate response to 1 g twice daily after 2 months, may increase dose to 3 g daily. Clinical improvement usually observed 1-2 months after initiating therapy. Concurrent use of analgesics and/or anti-inflammatory agents is recommended until therapeutic effect of sulfasalazine is observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis, inflammatory bowel disease, Crohn&rsquo;s disease:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Consider dose reduction or use of enteric coated tablet in patients experiencing adverse gastrointestinal effects with uncoated tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Acute attacks:",
"     </i>",
"     Severe: 1-2 g 3-4 times daily; mild-to-moderate: 1 g 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Maintenance of remission:",
"     </i>",
"     1 g 2-3 times daily; continue dose indefinitely unless patient experiences adverse effects. In the event patient condition worsens, increase dose to 1-2 g 3-4 times daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"      see \"Sulfasalazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Children &ge;6 years: Oral: Enteric coated tablet: 30-50 mg/kg/day in 2 divided doses; Initial: Begin with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of expected maintenance dose; increase weekly; maximum: 2 g daily typically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     Children &ge;6 years: Oral: Initial: 40-60 mg/kg/day in 3-6 divided doses; maintenance dose: 30 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Desensitization regimen:",
"     </i>",
"     Refer to adult dosing for patients who may be sensitive to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis, inflammatory bowel disease, Crohn&rsquo;s disease:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Consider dose reduction or use of enteric coated tablet in patients experiencing adverse gastrointestinal effects with uncoated tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute attacks:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body weight 25 to &lt;35 kg: 500 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body weight 35-50 kg: 1 g 2-3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance of remission:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body weight 25 to &lt;35 kg: 500 mg 2 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body weight 35-50 kg: 500 mg 2-3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F223909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F223910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azulfidine&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfazine: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azulfidine EN-tabs&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfazine EC: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F223886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be administered in evenly divided doses, preferably after meals. Enteric coated tablets should be swallowed whole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Treatment of mild-to-moderate ulcerative colitis or as adjunctive therapy in severe ulcerative colitis; enteric coated tablets are also used for rheumatoid arthritis (including juvenile idiopathic arthritis [JIA]) in patients who inadequately respond to analgesics and NSAIDs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Adjunctive therapy in severe ulcerative colitis, distal ulcerative colitis or proctitis, and Crohn&rsquo;s disease; enteric coated tablets are also used for rheumatoid arthritis unsuccessfully treated with first-line therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F223942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SulfaSALAzine may be confused with salsalate, sulfADIAZINE, sulfiSOXAZOLE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Azulfidine&reg; may be confused with Augmentin&reg;, azaTHIOprine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dyspepsia, gastric distress, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Oligospermia (reversible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cyanosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Heinz body anemia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (limited to important or life-threatening; includes reactions reported with mesalamine or other sulfonamides): Agranulocytosis, alopecia, anaphylaxis, aplastic anemia, arthralgia, ataxia, cholestatic jaundice, cirrhosis, crystalluria, depression, diarrhea, drowsiness, drug rash with eosinophilia and systemic symptoms (DRESS), eosinophilia, epidermal necrolysis, exfoliative dermatitis, fibrosing alveolitis, fulminant hepatitis, Guillain-Barr&eacute; syndrome, hallucinations, hearing loss, hemolytic-uremic syndrome, hematuria, hepatic failure, hepatic necrosis, hepatitis, hypoglycemia, hypoprothrombinemia, insomnia, interstitial lung disease, interstitial nephritis, jaundice, Kawasaki-like syndrome (single case report), lupus-like syndrome, megaloblastic anemia, meningitis, methemoglobinemia, myelitis, myelodysplastic syndrome, myocarditis (allergic), nephropathy (acute), nephrotic syndrome, neutropenia (congenital), neutropenic enterocolitis, pancreatitis, pericarditis, periorbital edema, peripheral neuropathy, photosensitization, pleuritis, pneumonitis, polyarteritis nodosa, proteinuria, purpura, rhabdomyolysis, seizure, serum sickness-like reactions, skin discoloration, Stevens-Johnson syndrome, thyroid function disturbance, tinnitus, urine discoloration, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfasalazine, sulfa drugs, salicylates, or any component of the formulation; porphyria; GI or GU obstruction",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Use in pediatric patients &lt;2 years of age; patients in whom acute asthmatic attacks, urticaria, rhinitis or other allergic manifestations are precipitated by acetyl salicylic acid (ASA) or other NSAIDs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia, and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions. Use with extreme caution in patients with blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Deaths from irreversible neuromuscular and central nervous system changes have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred with sulfonamides; discontinue use at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fibrosing alveolitis: Deaths from fibrosing alveolitis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Folate deficiency: May decrease folic acid absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: Nausea, vomiting, and abdominal discomfort commonly occur; titration of dose and/or using the enteric coated formulation may decrease GI adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with hepatic damage have occurred; discontinue use at first sign of jaundice or hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oligospermia: In males, oligospermia (rare) has been reported; usually reverses upon discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies/asthma: Use with caution in patients with severe allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolytic anemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with impaired hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with extreme caution in patients with renal impairment. Maintain adequate hydration to prevent crystalluria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Slow acetylators: Patients classified as slow acetylators may be at increased risk for adverse reactions due to a prolonged half-life of sulfapyrazine (metabolite of sulfasalazine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Enteric coated tablets: Discontinue if tablets are noted to pass without disintegrating.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: 5-ASA Derivatives may decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: SulfaSALAzine may enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: SulfaSALAzine may decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiopurine Analogs: 5-ASA Derivatives may decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: 5-ASA Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F223900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: May decrease folic acid absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9751041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Sulfasalazine and sulfapyridine cross the placenta; a potential for kernicterus in the newborn exists. Agranulocytosis was noted in an infant following maternal use of sulfasalazine during pregnancy. Based on available data, an increase in fetal malformations has not been observed following maternal use of sulfasalazine for the treatment of inflammatory bowel disease or ulcerative colitis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP recommends use &ldquo;with caution&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F223892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfasalazine is excreted in breast milk; sulfapyridine concentrations are ~30% to 60% of the maternal serum. Bloody stools or diarrhea have been reported in nursing infants. Although sulfapyridine has poor bilirubin-displacing ability, exposure may cause kernicterus in the newborn; use with caution in women who are breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F223893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfasalazine impairs folate absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F223891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Azulfidine EN-tabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $105.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (SulfaSALAzine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $38.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Sulfazine EC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $38.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Azulfidine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $80.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SulfaSALAzine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $24.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sulfazine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (180): $45.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9751223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and liver function tests (prior to therapy, then every other week for first 3 months of therapy, followed by every month for the second 3 months, then once every 3 months thereafter); periodic urinalysis and renal function tests; stool frequency; signs of infection",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15896591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfapyridine concentrations &gt;50 mcg/mL are associated with increased adverse events.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azulfidina (MX);",
"     </li>",
"     <li>",
"      Azulfidine (CN, DE, VE);",
"     </li>",
"     <li>",
"      Azulfidine EN-tabs (AR, CN);",
"     </li>",
"     <li>",
"      Azulfin (BR);",
"     </li>",
"     <li>",
"      Bomecon (TW);",
"     </li>",
"     <li>",
"      Colo-Pleon (DE);",
"     </li>",
"     <li>",
"      Disalazin (PE);",
"     </li>",
"     <li>",
"      Falazine (EC);",
"     </li>",
"     <li>",
"      Gastropyrin (FI);",
"     </li>",
"     <li>",
"      Lazafin (ID);",
"     </li>",
"     <li>",
"      Pyralin EN (AU);",
"     </li>",
"     <li>",
"      Rosulfant (CO);",
"     </li>",
"     <li>",
"      SAAZ (IN);",
"     </li>",
"     <li>",
"      Salazine (TH, TW);",
"     </li>",
"     <li>",
"      Salazodin (UY);",
"     </li>",
"     <li>",
"      Salazopirina (PT);",
"     </li>",
"     <li>",
"      Salazopyrin (AE, AT, AU, BH, CH, CY, DK, EG, ES, FI, GB, HN, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LY, NO, NZ, OM, PK, PL, QA, SA, SE, SY, TR, YE, ZA);",
"     </li>",
"     <li>",
"      Salazopyrin Entabs (AE, BH, CY, DK, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Salazopyrin-EN (AU, BG, CH, CO, CZ, EE, FI, GB, HK, IL, IT, KP, MY, NO, NZ, SE, TH, TW, ZA);",
"     </li>",
"     <li>",
"      Salazopyrina (ES);",
"     </li>",
"     <li>",
"      Salazopyrine (BE, FR, LU, NL);",
"     </li>",
"     <li>",
"      Salazopyrine EC (BE);",
"     </li>",
"     <li>",
"      Salivon (ID);",
"     </li>",
"     <li>",
"      Salopyr (FI);",
"     </li>",
"     <li>",
"      Salopyrine (GR);",
"     </li>",
"     <li>",
"      Saridine-E (HK, TH);",
"     </li>",
"     <li>",
"      Sulcolon (ID);",
"     </li>",
"     <li>",
"      Sulfasalazin (HR);",
"     </li>",
"     <li>",
"      Sulfitis (ID);",
"     </li>",
"     <li>",
"      Zopyrin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &le;15% as unchanged drug from small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Sulfasalazine: &gt;99% to albumin; Sulfapyridine: ~70% to albumin; Acetylsulfapyridine (AcSP): ~90% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Sulfasalazine ~7.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via colonic intestinal flora to sulfapyridine and 5-aminosalicylic acid (5-ASA). Following absorption, sulfapyridine undergoes acetylation to form AcSP and ring hydroxylation while 5-ASA undergoes N-acetylation (non-acetylation phenotype dependent process); rate of metabolism via acetylation dependent on acetylation phenotype",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Sulfasalazine: &lt;15%; Sulfapyridine: ~60%; 5-aminosalicylic acid: ~10% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Sulfasalazine: 5.7-10 hours (prolonged in elderly); Sulfapyridine: 14.8 hours (slow acetylators) and 10.4 hours (fast acetylators)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Sulfasalazine: 3-12 hours (mean: 6 hours); Metabolites: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug, conjugates, and acetylated metabolites); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ardizzone S and Porro GB, &ldquo;A Practical Guide to the Management of Distal Ulcerative Colitis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 55(4):519-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/9561342/pubmed\" id=\"9561342\" target=\"_blank\">",
"        9561342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1995, 42(5):1099-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/7567188/pubmed\" id=\"7567188\" target=\"_blank\">",
"        7567188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haas RM, Li P, and Chu JW, &ldquo;Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(9):2238-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/16123497/pubmed\" id=\"16123497\" target=\"_blank\">",
"        16123497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haines JD, Jr, &ldquo;Hepatotoxicity After Treatment With Sulfasalazine,&rdquo;",
"      <i>",
"       Postgrad Med",
"      </i>",
"      , 1986, 79(6):193-4, 197-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/2871549/pubmed\" id=\"2871549\" target=\"_blank\">",
"        2871549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jick H, Myers MW, and Dean AD, &ldquo;The Risk of Sulfasalazine- and Mesalazine-Associated Blood Disorders,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(2):176-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/7624265/pubmed\" id=\"7624265\" target=\"_blank\">",
"        7624265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jullien D, Wokenstein P, Roupie E, et al, &ldquo;Toxic Epidermal Necrolysis After Sulfasalazine Treatment of Mild Psoriatic Arthritis: Warning on the Use of Sulfasalazine for a New Indication,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1995, 38(4):573.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/7718014/pubmed\" id=\"7718014\" target=\"_blank\">",
"        7718014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Dell JR, &ldquo;Triple Therapy With Methotrexate, Sulfasalazine, and Hydroxychloroquine in Patients With Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Rheum Dis Clin North Am",
"      </i>",
"      , 1998, 24(3):465-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/9710881/pubmed\" id=\"9710881\" target=\"_blank\">",
"        9710881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Rossum MA, Fiselier TJ, Franssen MJ, et al, &ldquo;Sulfasalazine in the Treatment of Juvenile Chronic Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Dutch Juvenile Chronic Arthritis Study Group,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41(5):808-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/9588731/pubmed\" id=\"9588731\" target=\"_blank\">",
"        9588731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veale DJ, Ho M, and Morley KD, &ldquo;Sulfasalazine-Induced Lupus in Psoriatic Arthritis,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1995, 34(4):383-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/28/8647/abstract-text/7788157/pubmed\" id=\"7788157\" target=\"_blank\">",
"        7788157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9963 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8647=[""].join("\n");
var outline_f8_28_8647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223946\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223907\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223926\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223908\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223909\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223910\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223882\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223868\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223886\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223942\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223953\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223944\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223889\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223872\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300096\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223877\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223900\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223879\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9751041\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223913\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223892\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223893\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223891\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9751223\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896591\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223894\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223871\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223888\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9963|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12677?source=related_link\">",
"      Sulfasalazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=related_link\">",
"      Sulfasalazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_28_8648="Histology desmoplastic melanoma";
var content_f8_28_8648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Desmoplastic melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 522px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Low power light photomicrograph of a desmoplastic melanoma, showing a poorly circumscribed tumor with a marked fibrogenic stromal response. There is lentigo maligna overlying the dermal tumor (black arrows). Panel B: Higher power view light photomicrograph of a desmoplastic melanoma, showing that the malignant cells have hyperchromatic, elongated nuclei, resembling those of fibroblasts. The malignant spindle cells form long fascicles that dissect dermal collagen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8648=[""].join("\n");
var outline_f8_28_8648=null;
var title_f8_28_8649="MTX hepatotoxicity light";
var content_f8_28_8649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Histologic findings in methotrexate hepatotoxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spectrum of histologic changes in methotrexate hepatotoxicity includes steatosis (top left), stellate (Ito) cell hypertrophy (top right), anisonucleosis (nuclei of varying sizes, bottom left), and, on Masson stain, hepatic fibrosis (bottom right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joel M Kremer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8649=[""].join("\n");
var outline_f8_28_8649=null;
var title_f8_28_8650="Reactive airways dysfunction syndrome and irritant-induced asthma";
var content_f8_28_8650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reactive airways dysfunction syndrome and irritant-induced asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Jean-Luc Malo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Moira Chan-Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Catherine Lemi&egrave;re, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Denyse Gautrin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/28/8650/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/28/8650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive airways dysfunction syndrome (RADS) and irritant-induced asthma (IrIA) are closely related forms of asthma that result from the",
"    <strong>",
"     nonimmunologic",
"    </strong>",
"    provocation of prolonged bronchial hyperresponsiveness and airflow obstruction by inhaled irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Irritant-induced respiratory problems were initially described among industrial workers and World War I combatants in the early part of the 20th century [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These reports focused on acute effects such as pulmonary edema and death, but also described chronic respiratory sequelae of intense, brief exposure to inhaled irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, bronchitic symptoms, such as cough and wheezing, were described following a chlorine spill in 1969, although bronchial responsiveness was not assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/5\">",
"     5",
"    </a>",
"    ]. Persistent airway hyperresponsiveness was noted in five of seven subjects four years after an acute exposure to sulfur dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/6\">",
"     6",
"    </a>",
"    ]. Further studies have led to a growing awareness and understanding of reactive airways dysfunction syndrome and irritant-induced asthma, especially in firefighters, rescue personnel, and people living in the vicinity of the World Trade Center site in September 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of RADS and IrIA will be reviewed here. The diagnosis of asthma and the causes, evaluation and management of occupational asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14489?source=see_link\">",
"     \"Occupational asthma: Management, prognosis, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive airways dysfunction syndrome (RADS) is described as the development of respiratory symptoms in the minutes or hours after a single accidental inhalation of a high concentration of irritant gas, aerosol, or smoke; these initial symptoms are followed by asthma-like symptoms and airway hyperresponsiveness that persist for a prolonged period (",
"    <a class=\"graphic graphic_table graphicRef77064 \" href=\"UTD.htm?11/57/12187\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1\">",
"     1",
"    </a>",
"    ]. RADS can occur after exposure to a variety of chemicals generated as gas or aerosol, or exposure to high levels of particulates (",
"    <a class=\"graphic graphic_table graphicRef55545 graphicRef68367 \" href=\"UTD.htm?2/1/2079\">",
"     table 2A-B",
"    </a>",
"    ). Clinical and functional criteria for the diagnosis of reactive airways dysfunction syndrome are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77064 \" href=\"UTD.htm?11/57/12187\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Irritant-induced asthma (IrIA) is a more general term to describe an asthmatic syndrome that results from a single or multiple high dose exposures to irritant products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/9\">",
"     9",
"    </a>",
"    ]. When only a single, high-dose exposure has been responsible, the term RADS is used. IrIA caused by single or multiple exposures to low doses of irritants has been reported, as after the World Trade Center catastrophe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Multiple exposures to high concentrations of products, such as chlorine in pulp and paper mills, may be obvious enough for the affected person to identify the timing, nature, and frequency of events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. When IrIA is caused by workplace exposures, it is considered a type of occupational asthma, the non-immunologic type.",
"   </p>",
"   <p>",
"    It has been suggested that IrIA also include the situation where multiple exposures to low concentrations of an irritant have led to bronchial mucosal injury and persistent asthma-like symptoms, although this is less well-established [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/11\">",
"     11",
"    </a>",
"    ]. The term \"low-dose RADS\" has been used to describe individuals in the latter group, although the background of repeated low-dose (as opposed to a single high-dose) exposure means that they do not formally fulfill the original criteria for RADS; we prefer the term IrIA for these patients. In addition, when the intensity of the exposure is less, but is of greater duration (eg, &gt;24 hours), symptoms may start after several hours or days, rather than within minutes of inhalation, thus further \"widening the spectrum of irritant-induced asthma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/12\">",
"     12",
"    </a>",
"    ]. The term Low Intensity Chronic Exposure Dysfunction Syndrome (LICEDS) has also been suggested to describe this form of IrIA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;RADS may occur after inhalational accidents at home, in the workplace, or in the general environment. IrIA due to multiple exposures is most commonly associated with inhaled irritants in the workplace. It is estimated that 60,000 inhalational accidents occur in the home and lead to medical consultation yearly in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/14\">",
"     14",
"    </a>",
"    ]. Industrial accidents also have the potential to expose nonemployees to noxious inhalants; the release of isocyanates at Bhopal, for example, led to more than 2000 deaths due to pulmonary edema, and caused RADS in many others [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimating the incidence of RADS is difficult for several reasons. Precise, subject-specific information regarding the duration and magnitude of exposure at the time of an accident is rarely available. This is further complicated in IrIA, where multiple exposures to irritant products are involved; the level of exposure to the inhaled irritant can vary between exposures and between exposed subjects; and several irritant agents can also be involved simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The size of populations at risk after an incident can only be determined approximately in many cases.",
"   </p>",
"   <p>",
"    The following observations, in which large numbers of patients were exposed to a chemical irritant, illustrate the variation in reported rates of development of RADS and IrIA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After an accidental exposure to high concentrations of glacial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      , the incidence of RADS among 51 hospital employees who were present during the 2.5 hours immediately following the accident was 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 289 workers exposed to chlorine gas in a pulp and paper mill, 71 (25 percent) developed respiratory symptoms shortly after the event [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/20\">",
"       20",
"      </a>",
"      ]. Among 239 workers with repeated exposures to chlorine and other gases over a 3-year period, significant respiratory symptoms were reported by 38 (16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/18\">",
"       18",
"      </a>",
"      ]. No association between exposure level and persistence of symptoms was documented. Subsequently, a longitudinal follow-up of the same workers over a 3-year period showed: (1) an effect on airway function related to the estimated number of symptomatic exposures and incidents, mostly among smokers; (2) a detectable increase in airway responsiveness associated with gassing incidents [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Professional cleaning is considered a high risk occupation for occupational asthma based on studies conducted in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/22\">",
"       22",
"      </a>",
"      ] and in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/23\">",
"       23",
"      </a>",
"      ]. Among 123 cases of work-related IrIA in one report, the most common class of agents was cleaning materials, which were associated with 18 (15 percent) of the IrIA cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 15 percent of all cases of occupational asthma accepted for compensation in Ontario, Canada, were of the RADS type [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/25\">",
"       25",
"      </a>",
"      ]; a similar proportion (14 percent) was found in a sentinel notification program in four states in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of studies have assessed the effects of exposure to the plume of particulate dust and smoke due to the fires and structural collapse of the World Trade Center towers on September 11, 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/7,8,26,27\">",
"       7,8,26,27",
"      </a>",
"      ]. The rate of newly diagnosed asthma among workers and volunteers was almost 4 percent and correlated with an earlier time of arrival and greater duration of time at the site [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/26,28\">",
"       26,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31976583\">",
"    <span class=\"h1\">",
"     CAUSES AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of RADS and IrIA are incompletely characterized, but appear to include the chemical and physical nature and concentration of the irritant agent in addition to certain host factors such as atopy and cigarette smoking.",
"   </p>",
"   <p>",
"    Increased concentrations of offending agents are associated with higher risk, and vapors and wet aerosols generally appear to be more provocative of RADS than dry particulates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/19\">",
"     19",
"    </a>",
"    ]. Workers exposed to bleaching agents in paper mills (including chlorine) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/29\">",
"     29",
"    </a>",
"    ] and cleaning products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/23\">",
"     23",
"    </a>",
"    ] are particularly at risk. Excess rates of asthma have been documented in workers exposed to cleaning agents, and",
"    <span class=\"nowrap\">",
"     RADS/IrIA",
"    </span>",
"    may explain this phenomenon (",
"    <a class=\"graphic graphic_table graphicRef55545 \" href=\"UTD.htm?34/4/34893\">",
"     table 2A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68367 \" href=\"UTD.htm?31/32/32269\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atopy has been described as a risk factor for the occurrence of the not so sudden onset variant of IrIA that develops days after an irritant exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, previously documented bronchial hyperresponsiveness did not predispose to the development of RADS in firefighters at the World Trade Center [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/31\">",
"     31",
"    </a>",
"    ]. It is likely that the preexisting airway hyperresponsiveness was infrequent among these firefighters given that asthma is an exclusion criterion for recruitment.",
"   </p>",
"   <p>",
"    Smoking is more common among workers with RADS than those with occupational asthma and seems to increase the risk of functional decline in workers repeatedly exposed to puffs of chlorine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/21,25\">",
"     21,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798536\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CORRELATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial observations from two cases of RADS illustrate the histopathologic features of the disease (",
"    <a class=\"graphic graphic_table graphicRef78151 \" href=\"UTD.htm?33/63/34811\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The initial change was rapid denudation of the mucosa with a fibrinohemorrhagic exudate in the submucosa. This was followed by subepithelial edema and signs of regeneration of the epithelial layer with proliferation of basal and parabasal cells. Desquamation, subepithelial fibrosis, thickening of the basement membrane, and regeneration of basal cells are all more striking in RADS than in occupational asthma with a latency period (",
"    <a class=\"graphic graphic_table graphicRef80475 \" href=\"UTD.htm?18/17/18715\">",
"     table 4",
"    </a>",
"    ). In addition, bronchoalveolar lavage reveals neutrophilia in the acute stage of RADS, whereas lymphocytes and eosinophils are more numerous in occupational asthma with a latency period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=see_link&amp;anchor=H3#H3\">",
"     \"Occupational asthma: Pathogenesis\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute changes of RADS have been reproduced by exposing rats to high concentrations of gaseous chlorine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/34\">",
"     34",
"    </a>",
"    ]. Histologic evaluation revealed epithelial flattening, necrosis, and evidence of epithelial regeneration. Bronchoalveolar lavage showed an increased number of neutrophils. Abnormalities in epithelial pathology and bronchial hyperresponsiveness were most prominent one to three days following injury. Epithelial abnormalities persisted in some animals for up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar findings have been described in a mouse model of RADS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/35\">",
"     35",
"    </a>",
"    ]. The long term (approximately 10 years) pathological abnormalities of RADS have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/36\">",
"     36",
"    </a>",
"    ]. Bronchial biopsies obtained in 10 subjects showed neutrophilic and eosinophilic inflammation. In addition, basement membranes were thicker among patients with RADS than those with mild immunologic OA or healthy controls.",
"   </p>",
"   <p>",
"    In one patient with irritant-induced asthma secondary to multiple exposures, an inflammatory infiltrate consisting of lymphocytes and polymorphonuclear cells was found on bronchial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/37\">",
"     37",
"    </a>",
"    ]. In the chronic stage of irritant-induced asthma, the infiltrate consisted of lymphocytes and eosinophils, with thickening of connective tissue and deposition of collagen fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of RADS and IrIA differ mainly in the rapidity of onset of symptoms. In RADS, the onset of symptoms is usually so abrupt that subjects are able to date their occurrence precisely, although a few patients report respiratory symptoms developing up to seven days after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/10,39\">",
"     10,39",
"    </a>",
"    ]. Patients with multiple exposures to high concentrations of products such as chlorine may be able to identify the timing, nature, and frequency of events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, patients with IrIA may not be aware of multiple low level irritant exposures and may report episodic symptoms that are not precisely linked to known exposures.",
"   </p>",
"   <p>",
"    After an acute exposure to gas, smoke, fumes, or vapors with irritant properties, subjects with no history of respiratory complaints report a burning sensation in the throat and nose referred to as RUDS (Respiratory Upper Airways Distress Syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/40\">",
"     40",
"    </a>",
"    ], in addition to cough, dyspnea, wheeze, and chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1,19,41\">",
"     1,19,41",
"    </a>",
"    ]. These symptoms typically develop within 24 hours of the exposure and are severe enough that approximately 78 percent seek emergency room treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/24\">",
"     24",
"    </a>",
"    ]. In most series, cough is the predominant symptom in RADS and IrIA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1,42,43\">",
"     1,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with IrIA due to multiple low level exposures to irritant agents describe essentially the same symptoms as patients with RADS (eg, cough, dyspnea, chest tightness, and wheezing), although the time course of onset differs. Symptoms of nasal mucosal irritation, such as nasal congestion, sneezing, nasal pruritus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased nasal secretions, may accompany the asthma-like symptoms and are often exacerbated by recurrent exposure in the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Occupational rhinitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For both RADS and IrIA, physical examination findings are not well described, but have included conjunctivitis, pharyngeal erythema, tearing, tachypnea, and wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/20,46\">",
"     20,46",
"    </a>",
"    ]. After an accidental chlorine exposure, 67 percent (42 of 63) had wheezing on initial presentation, and 84 percent had wheezing at some point in their hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/41\">",
"     41",
"    </a>",
"    ]. Exposure to ammonia may be associated with burns and blisters on exposed skin and damage to the surface structures of the eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link&amp;anchor=H33#H33\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\", section on 'Pulmonary irritants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4797885\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with the acute onset of respiratory symptoms following an irritant exposure typically includes assessment of oxygenation by pulse oximetry or arterial blood gases and a chest radiograph to look for noncardiogenic pulmonary edema, pneumonia, or other causes of dyspnea. As soon as possible, spirometry is performed to determine whether airflow limitation is present and reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important component of the evaluation is to review the details of the history, particularly when the patient is seen weeks or months after the initial exposure. Some relevant questions to be asked to all subjects when first assessed for possible asthma, and particularly for RADS or IrIA, are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef68098 \" href=\"UTD.htm?39/14/40171\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients with persistent symptoms due to RADS or IrIA, the evaluation is the same for the two processes. In addition to spirometry, additional tests include more complete pulmonary function testing with assessment of nonspecific hyperresponsiveness. An approach to the patient with dyspnea is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798684\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory testing is usually not helpful in the diagnosis of irritant exposures. However, a complete blood count and differential are appropriate to help exclude other processes in the differential diagnosis of dyspnea such as anemia, eosinophilic pneumonia, and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798305\">",
"    <span class=\"h2\">",
"     Skin and immunologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with chronic symptoms due to RADS or IrIA, either allergy skin testing or immunoassay to a panel of common aeroallergens is appropriate to exclude allergic asthma due to common aeroallergens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro immunoassay for IgE antibodies to occupational sensitizers is available for a limited number of low molecular weight chemical-protein conjugates (eg, diisocyanates), but these are not standardized or commercially available. An acute increase in specific IgE antibodies to formaldehyde has been described in a case of RADS associated with high level exposure to formaldehyde, although the significance of this observation is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4797893\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first steps in the evaluation of a patient with respiratory symptoms after an irritant inhalational exposure is pulmonary function testing to assess the presence, severity, and reversibility of airflow limitation. For patients without significant airflow obstruction, bronchoprovocation challenge can be used to document airways hyperresponsiveness. The roles of spirometry and bronchoprovocation challenge in the diagnosis of asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Measures of airflow limitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798231\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline spirometry is obtained in all patients suspected of having RADS or IrIA; bronchodilator reversibility assessed if airflow limitation is present. In a series of 19 patients seen after chlorine exposure, approximately half had airflow limitation when assessed soon after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/48\">",
"     48",
"    </a>",
"    ]. Among 10 subjects with RADS due to high level exposures to a variety of agents, four had airflow obstruction with a forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) that was less than 80 percent of predicted when assessed in a subspecialty clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Measures of airflow limitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following baseline spirometry, bronchodilator reversibility is assessed by inhalation of a short-acting beta agonist. In general, reversibility is defined as an increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 12 percent or more, accompanied by an absolute increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of at least 200 mL. Airflow obstruction is generally less responsive to bronchodilator in RADS than in asthma, although some degree of reversibility may be present. A comparison of 30 subjects with immunologic occupational asthma and 15 subjects with RADS found a mean improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    after bronchodilator of close to 20 percent in the subjects with immunologic occupational asthma, nearly double the response seen among those with RADS. However, significant heterogeneity was seen among the RADS group:6 of the 15 subjects had a postbronchodilator improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of more than 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a minority of patients, a restrictive defect is noted on pulmonary function testing, although an obstructive pattern is much more common (",
"    <a class=\"graphic graphic_figure graphicRef59123 \" href=\"UTD.htm?31/12/31949\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Lung volumes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798224\">",
"    <span class=\"h3\">",
"     Nonspecific bronchoprovocation challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;If baseline spirometry shows absent or minimal airflow limitation (eg, an FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 70 percent of predicted or greater) and no significant bronchodilator reversibility, nonspecific bronchial challenge (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ) is performed to assess for bronchial hyperreactivity. The contraindications to bronchoprovocation challenge and adjustments to medications prior to testing are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef82058 \" href=\"UTD.htm?23/61/24539\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62151 \" href=\"UTD.htm?7/29/7645\">",
"     table 7",
"    </a>",
"    ). The performance of bronchoprovocation challenge is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H9#H9\">",
"     \"Bronchoprovocation testing\", section on 'Pharmacologic challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among various case reports, a positive bronchoprovocation challenge was present at initial evaluation in virtually all patients who were able to perform the testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798276\">",
"    <span class=\"h3\">",
"     Specific bronchoprovocation challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific bronchoprovocation challenge to sensitizing agents in the workplace is occasionally used in the evaluation of immunologic occupational asthma to ascertain the specific causative agent. However, specific challenge with agents that are known to cause IrIA is not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"     \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an exception to avoiding specific bronchoprovocation in RADS and IrIA, specific inhalational challenge has been performed in a patient who developed RADS following a high level exposure to diisocyanate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/50\">",
"     50",
"    </a>",
"    ]. Diisocyanate is a cause of immunologic occupational asthma among workers with frequent low level exposures. Bronchoprovocation challenge was positive, and the patient subsequently developed immunological occupational asthma associated with nonirritant exposures to the same agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H344156515#H344156515\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Low-molecular-weight'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"     \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798648\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is typically obtained to exclude noncardiogenic pulmonary edema or pneumonia in patients presenting after an acute irritant exposure or other causes of dyspnea in those presenting later in the course of RADS or after multiple lower dose irritant exposures. The chest radiograph in patients with RADS and IrIA is typically normal or hyperinflated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\", section on 'Chest x-ray (CXR)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link&amp;anchor=H2084352#H2084352\">",
"     \"Approach to the patient with dyspnea\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) is not usually required in the evaluation of RADS or IrIA, but may be performed in atypical cases to exclude alternative diagnoses. HRCT scans, obtained in 29 symptomatic rescue and recovery workers at the World Trade Center site, showed evidence of air-trapping based on a mosaic pattern on the end-expiratory images in 25 of these workers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RADS and IrIA is based upon a combination of exposure history (",
"    <a class=\"graphic graphic_table graphicRef68098 \" href=\"UTD.htm?39/14/40171\">",
"     table 5",
"    </a>",
"    ), time course of symptom onset, and evidence of reversible airflow limitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airways hyperresponsiveness.",
"   </p>",
"   <p>",
"    The diagnosis of RADS is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of acute exposure to an irritant agent or material preceding the onset of respiratory symptoms (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Acute onset of respiratory symptoms within 24 hours of the exposure, or within seven days at the latest (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Persistence of airway obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperresponsiveness, generally for three months or more (see",
"      <a class=\"local\" href=\"#H4797893\">",
"       'Pulmonary function testing'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of IrIA is often not as straightforward as the diagnosis of RADS due to the lack of a single episode of high level exposure. However, a history of single or multiple exposures to an irritating inhalational agent (",
"    <a class=\"graphic graphic_table graphicRef68098 \" href=\"UTD.htm?39/14/40171\">",
"     table 5",
"    </a>",
"    ), the presence of asthma-like symptoms, and the presence of reversible airway obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperresponsiveness are necessary to the diagnosis. (See",
"    <a class=\"local\" href=\"#H4797893\">",
"     'Pulmonary function testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The absence of specific testing that can establish a causal role of an irritant agent makes it difficult to establish the diagnosis of irritant-induced asthma with certainty. However, data from epidemiologic studies that have identified occupations with an increased risk of asthma, such as cleaners [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/30,52\">",
"     30,52",
"    </a>",
"    ] and pulp mill workers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/29\">",
"     29",
"    </a>",
"    ], can be used to support a diagnosis of IrIA in a patient with similar exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361579\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301455\">",
"    <span class=\"h2\">",
"     Acute presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of an acute presentation with possible RADS, the differential includes underlying asthma that may have been exacerbated by an irritant exposure, acute respiratory infection, noncardiogenic pulmonary edema, and other causes of an acute onset of dyspnea. A careful history provides guidance regarding the severity of the exposure and thus the likelihood of RADS versus an exacerbation of underlying asthma. A conventional chest radiograph can help exclude pneumonia, noncardiogenic pulmonary edema, and acute eosinophilic pneumonia. A complete blood count and differential provides supportive information for or against infectious or eosinophilic pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301462\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with persistent symptoms, the differential diagnosis of RADS and IrIA typically includes underlying asthma that may have been exacerbated by an irritant exposure, occupational asthma due to an immunologic reaction to an agent in the workplace, paradoxical motion of the vocal cord (also known as vocal cord dysfunction or irritable larynx syndrome), and nonasthmatic eosinophilic bronchitis.",
"   </p>",
"   <p>",
"    A history of prior symptoms of cough or dyspnea, possibly exacerbated by respiratory infection or exposure to irritants, favors a diagnosis of pre-existing asthma.",
"   </p>",
"   <p>",
"    A number of features are common to IrIA and immunologic occupational asthma. Wheezing and airflow obstruction are common to both conditions. A differentiating feature is that immunologic occupational asthma is reproduced by inhalation challenge with low levels of the offending workplace agent, while RADS and irritant-induced asthma are not (",
"    <a class=\"graphic graphic_table graphicRef80475 \" href=\"UTD.htm?18/17/18715\">",
"     table 4",
"    </a>",
"    ). Differentiation may also be based on the type of exposure. As an example, exposure to chlorine and cleaning agents is associated with IrIA, while exposure to flour and latex is associated with occupational asthma. A few of these agents, however, have been associated with both syndromes (eg, diisocyanates, cleaning agents). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4797893\">",
"     'Pulmonary function testing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H1191269#H1191269\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Causative agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paradoxical vocal cord motion (PVCM) refers to abnormal closure of the vocal cords, usually on inspiration; it may mimic asthma or accompany asthma. A temporal association of onset of PVCM and irritant exposure has been described, adding to the importance of differentiating these entities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/53\">",
"     53",
"    </a>",
"    ]. The diagnosis of PVCM is usually suggested by the presence of dysphonia and abnormal slowing of the inspiratory flow volume loop obtained during routine spirometry or nonspecific bronchoprovocation challenge. The diagnosis is confirmed by direct visualization of the vocal cords by laryngoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link&amp;anchor=H11#H11\">",
"     \"Paradoxical vocal cord motion\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H9#H9\">",
"     \"Bronchoprovocation testing\", section on 'Pharmacologic challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonasthmatic eosinophilic bronchitis (NAEB) is characterized by a cough that is usually nonproductive, eosinophilia in induced sputum, and the absence of airflow limitation or bronchial hyperresponsiveness. Nonasthmatic eosinophilic bronchitis has been described in workers exposed to a variety of occupational agents that are associated with IgE-mediated sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/2,54,55\">",
"     2,54,55",
"    </a>",
"    ]. The key differentiating feature is the negative bronchoprovocation challenge among patients with NAEB. Induced sputum shows eosinophils in NAEB. However, induced sputum analysis has not been fully evaluated in RADS and IrIA and is not widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4798224\">",
"     'Nonspecific bronchoprovocation challenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92154380\">",
"    <span class=\"h2\">",
"     Acute management of RADS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of an acute presentation of RADS is essentially the same as the treatment of an acute asthma exacerbation (",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54125 \" href=\"UTD.htm?32/57/33693\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/38\">",
"     38",
"    </a>",
"    ]. Bronchodilator therapy is administered based on the severity of symptoms and response to treatment, even though the response to inhaled bronchodilator may be blunted compared to asthma. If a short-acting beta-agonist (SABA) does not provide adequate symptomatic relief, we typically add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    , although data in support of this are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4798231\">",
"     'Spirometry'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of acute RADS includes prompt administration of systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg daily) for patients with moderate to severe symptoms and a forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) less than 70 percent predicted. No formal trials have been performed on glucocorticoid therapy in RADS, so the use of systemic glucocorticoids for RADS is based upon clinical experience and their well-documented role in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Support for systemic glucocorticoid therapy comes from their use in an animal model of RADS. Parenteral glucocorticoids, given for one week immediately after exposure, significantly attenuated expected increases in lung resistance and bronchial hyperresponsiveness; bronchoalveolar lavage (BAL) and histologic parameters were likewise improved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically continue oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for 10 to 15 days, which is longer than that used for typical exacerbations of asthma, as it is our clinical observation that patients improve slowly and do not tolerate tapering sooner. When systemic glucocorticoids are discontinued, we initiate high-dose inhaled glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    2000",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    or the equivalent) and taper as tolerated. Relatively high doses of inhaled glucocorticoids may be required for long-term treatment as pathological evidence shows the persistence of eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who have a documented irritant exposure but whose initial symptoms and airflow obstruction are less severe (eg, FEV",
"    <sub>",
"     1",
"    </sub>",
"    &ge;70 percent predicted), we suggest initiation of inhaled glucocorticoids rather than systemic glucocorticoids or inhaled beta-agonist therapy alone. Data in support of inhaled glucocorticoids are limited, but a case report of a subject with RADS reflects our experience. In the report, treatment with inhaled glucocorticoids normalized bronchial hyperresponsiveness, but hyperresponsiveness worsened when therapy was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial dose of inhaled glucocorticoids is based on the step-wise approach to asthma outlined in the National Asthma Education and Prevention Program (NAEPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]; in our experience the majority of patients require a high dose to control symptoms (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H22#H22\">",
"     \"An overview of asthma management\", section on 'Initiating therapy in previously untreated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once patients have demonstrated symptomatic improvement, inhaled glucocorticoids can be tapered as tolerated. Airflow limitation is assessed serially with spirometry as the inhaled glucocorticoids are tapered. If asthma has remained well-controlled for several weeks and the FEV",
"    <sub>",
"     1",
"    </sub>",
"    is stable, then the inhaled glucocorticoids are decreased by 25 to 50 percent increments. When the FEV",
"    <sub>",
"     1",
"    </sub>",
"    is greater than 70 percent of predicted, bronchial responsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    may be used to guide tapering inhaled glucocorticoids, although this approach is not well-validated. The weaning of inhaled glucocorticoids may take six weeks to six months, and many patients require more long-term therapy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Prognosis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92154406\">",
"    <span class=\"h2\">",
"     Management of chronic RADS or IrIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with RADS or IrIA who require long-term pharmacologic treatment for asthma symptoms, the step-wise approach described in the NAEPP and the Global Initiative for Asthma (GINA) guidelines is followed even though it has not been formally assessed in this setting (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Over time, if the patient&rsquo;s asthma remains well-controlled, therapy is tapered according to the same guidelines. The long-term treatment of RADS and IrIA is the same, even though the specific timing and pattern of onset differ. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H27#H27\">",
"     \"An overview of asthma management\", section on 'Assessing control to adjust therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic treatment of RADS and IrIA has not been studied directly; however, based on clinical experience patients are advised to avoid exposure to other respiratory irritants, including cigarette smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/56\">",
"     56",
"    </a>",
"    ]. For those patients who have underlying atopy, avoidance of known allergens to which they are sensitive is also appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4798774\">",
"    <span class=\"h1\">",
"     EXPOSURE AVOIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete exposure avoidance is the preferred option for workers with IrIA. While low dose exposures to irritant agents appear less likely to cause an increase in symptoms, compared with immunologic inciting agents, the exact risk is not known. On the other hand, workers whose asthma symptoms and physiology have normalized may find it necessary to return to work. The risk of a high-level exposure to appropriate engineering controls and respiratory protective devices should be in place to minimize the risk of worsening IrIA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/2\">",
"     2",
"    </a>",
"    ]. Ongoing monitoring of symptoms and respiratory physiology is key to early identification of any deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of acute RADS and irritant-induced asthma is unclear as longitudinal, prospective data are limited. The available evidence suggests a range of responses from complete clearance of symptoms and signs to persistent respiratory disability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/36,42,44,45,58-60\">",
"     36,42,44,45,58-60",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 20 patients who had repeated exposures to chlorine gas during a three-month period, two-thirds still had an abnormal response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      three years later, and 85 percent reported wheezing, shortness of breath, or cough [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/58\">",
"       58",
"      </a>",
"      ]. In a separate series of 71 workers suspected to have RADS following exposures to chlorine, 90 percent had persistent respiratory symptoms 18 to 24 months after exposure and 57 percent had bronchial hyperresponsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based study of 145 subjects exposed to chlorine gas found no changes in pulmonary function testing over the six-year follow-up period; however, airway responsiveness was not assessed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 10-year follow-up of 197 veterans of the Iran-Iraq war with acute poisoning with sulfur mustard gas, asthma symptoms, reversible airflow obstruction, and excessive diurnal peak expiratory flow variability were present in 11 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/60\">",
"       60",
"      </a>",
"      ]. In addition, chronic bronchitis or bronchiectasis occurred in 68 percent of patients, presumably due to extensive bronchial necrosis following acute exposure.",
"     </li>",
"     <li>",
"      Among 35 workers with occupational IrIA, almost all continued to have symptoms consistent with asthma and one-third were still using inhaled glucocorticoids at follow up eight or more years later [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/42\">",
"       42",
"      </a>",
"      ]. Spirometry was persistently abnormal in 74 percent. Among 23 who had repeat measurements of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      responsiveness, nine (25 percent) were no longer hyperresponsive. Bronchial biopsies were performed in 10 subjects at a mean of 10.9 years following the initial exposure and eosinophilic inflammation similar to that found in subjects with mild to moderate asthma was noted, but with more pronounced basement membrane thickening [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 13,954 Fire Department of New York City rescue workers present on the site of the World Trade Center in September 2001, 91.6 percent participated in a routine surveillance program. After a median of 6.1 years of follow-up, the significant declines in FEV",
"      <sub>",
"       1",
"      </sub>",
"      seen during the first year persisted without recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/49,61\">",
"       49,61",
"      </a>",
"      ]. Greater than normal lung functions declines were associated with initial bronchodilator response and weight gain in a five year follow-up by the World Trade Center Worker and Volunteer Monitoring Program [",
"      <a class=\"abstract\" href=\"UTD.htm?8/28/8650/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31975798\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritant-induced asthma (IrIA) is a general term to describe an asthmatic syndrome that results from single or multiple exposures to irritant products (",
"      <a class=\"graphic graphic_table graphicRef55545 \" href=\"UTD.htm?34/4/34893\">",
"       table 2A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68367 \" href=\"UTD.htm?31/32/32269\">",
"       table 2B",
"      </a>",
"      ) that induce nonimmunologic bronchial hyperresponsiveness. When symptoms promptly follow a single high-dose exposure, the syndrome is called RADS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute symptoms associated with RADS include a rapid onset of a burning sensation in the throat and nose, chest pain, dyspnea, cough and wheeze. In IrIA, the symptoms are similar, but the onset is less acute than with RADS. Questions that are helpful in the evaluation of RADS and IrIA are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef68098 \" href=\"UTD.htm?39/14/40171\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RADS requires the combination of exposure to a high-dose of an inhalational irritant, onset of symptoms within hours (rarely days), and evidence of reversible airflow limitation (eg, spirometry with bronchodilator reversibility or positive bronchoprovocation challenge), although a restrictive defect can also be present. A chest radiograph is often obtained to exclude other causes of dyspnea. Criteria for the diagnosis of RADS are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef77064 \" href=\"UTD.htm?11/57/12187\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4797885\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of IrIA is based upon a history of single or multiple exposures to an irritating inhalational agent, the presence of asthma-like symptoms, and the presence of reversible airway obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperresponsiveness. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4797893\">",
"       'Pulmonary function testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with the acute onset of RADS, we recommend using the same treatment protocol that is used for an acute asthma exacerbation (",
"      <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54125 \" href=\"UTD.htm?32/57/33693\">",
"       table 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66549 \" href=\"UTD.htm?0/12/204\">",
"       table 11",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). As patients improve, glucocorticoid therapy is transitioned from oral to inhaled; in our experience high dose inhaled glucocorticoids are often needed to control symptoms (",
"      <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"       table 10",
"      </a>",
"      ). Inhaled rather than oral glucocorticoids are appropriate initial therapy for patients who present with less severe symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of acute exacerbations of asthma in adults\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with persistent symptoms due to RADS or IrIA, we suggest following the step-wise approach used in asthma management (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 9",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, patients are advised to avoid respiratory irritants, including cigarette smoke, and allergens to which they are sensitive. (See",
"      <a class=\"local\" href=\"#H92154406\">",
"       'Management of chronic RADS or IrIA'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"       \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete exposure avoidance is the preferred option for workers with IrIA. Cautious return to work may be acceptable for patients with IrIA or RADS if the following conditions are met: symptoms are well-controlled, appropriate engineering controls and personal protective equipment are in place to minimize exposure, and the worker has ongoing monitoring for any deterioration in respiratory status. (See",
"      <a class=\"local\" href=\"#H4798774\">",
"       'Exposure avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with RADS and IrIA improve over time, although many continue to have some respiratory symptoms for at least a year and have physiologic abnormalities such as bronchial hyperreactivity for several years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/1\">",
"      Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS). Persistent asthma syndrome after high level irritant exposures. Chest 1985; 88:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/2\">",
"      Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/3\">",
"      Das R, Blanc PD. Chlorine gas exposure and the lung: a review. Toxicol Ind Health 1993; 9:439.",
"     </a>",
"    </li>",
"    <li>",
"     Winternitz, MC. Collected studies on the pathology of war gas poisoning, Yale University Press, New Haven 1920. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/5\">",
"      Weill H, George R, Schwarz M, Ziskind M. Late evaluation of pulmonary function after acute exposure to chlorine gas. Am Rev Respir Dis 1969; 99:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/6\">",
"      H&auml;rk&ouml;nen H, Nordman H, Korhonen O, Winblad I. Long-term effects of exposure to sulfur dioxide. Lung function four years after a pyrite dust explosion. Am Rev Respir Dis 1983; 128:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/7\">",
"      Prezant DJ, Weiden M, Banauch GI, et al. Cough and bronchial responsiveness in firefighters at the World Trade Center site. N Engl J Med 2002; 347:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/8\">",
"      Banauch GI, Alleyne D, Sanchez R, et al. Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center. Am J Respir Crit Care Med 2003; 168:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/9\">",
"      Lemi&egrave;re C, Malo JL, Gautrin D. Nonsensitizing causes of occupational asthma. Med Clin North Am 1996; 80:749.",
"     </a>",
"    </li>",
"    <li>",
"     Gautrin, D, Bernstein, IL, Brooks, S. Reactive airways dysfunction syndrome or irritant-induced asthma. In: Asthma in the workplace, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Marcel Dekker Inc, New York 1999. p.565.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/11\">",
"      Kipen HM, Blume R, Hutt D. Asthma experience in an occupational and environmental medicine clinic. Low-dose reactive airways dysfunction syndrome. J Occup Med 1994; 36:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/12\">",
"      Brooks SM, Hammad Y, Richards I, et al. The spectrum of irritant-induced asthma: sudden and not-so-sudden onset and the role of allergy. Chest 1998; 113:42.",
"     </a>",
"    </li>",
"    <li>",
"     Gautrin D, et al.. Reactive airways dysfunction syndrome and irritant-induced asthma. In: Asthma in the workplace, 3rd ed, Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI.  (Eds), Taylor &amp; Francis, New York 2006. p.581.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/14\">",
"      Blanc PD, Galbo M, Hiatt P, et al. Symptoms, lung function, and airway responsiveness following irritant inhalation. Chest 1993; 103:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/15\">",
"      Cullinan P, Acquilla S, Dhara VR. Respiratory morbidity 10 years after the Union Carbide gas leak at Bhopal: a cross sectional survey. The International Medical Commission on Bhopal. BMJ 1997; 314:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/16\">",
"      Dhara VR, Cullinan P. Bhopal priorities. Int J Occup Environ Health 2004; 10:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/17\">",
"      Tarlo SM. Workplace irritant exposures: do they produce true occupational asthma? Ann Allergy Asthma Immunol 2003; 90:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/18\">",
"      Gautrin D, Leroyer C, L'Archev&ecirc;que J, et al. Cross-sectional assessment of workers with repeated exposure to chlorine over a three year period. Eur Respir J 1995; 8:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/19\">",
"      Kern DG. Outbreak of the reactive airways dysfunction syndrome after a spill of glacial acetic acid. Am Rev Respir Dis 1991; 144:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/20\">",
"      Bh&eacute;rer L, Cushman R, Courteau JP, et al. Survey of construction workers repeatedly exposed to chlorine over a three to six month period in a pulpmill: II. Follow up of affected workers by questionnaire, spirometry, and assessment of bronchial responsiveness 18 to 24 months after exposure ended. Occup Environ Med 1994; 51:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/21\">",
"      Gautrin D, Leroyer C, Infante-Rivard C, et al. Longitudinal assessment of airway caliber and responsiveness in workers exposed to chlorine. Am J Respir Crit Care Med 1999; 160:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/22\">",
"      Kogevinas M, Ant&oacute; JM, Sunyer J, et al. Occupational asthma in Europe and other industrialised areas: a population-based study. European Community Respiratory Health Survey Study Group. Lancet 1999; 353:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/23\">",
"      Rosenman KD, Reilly MJ, Schill DP, et al. Cleaning products and work-related asthma. J Occup Environ Med 2003; 45:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/24\">",
"      Henneberger PK, Derk SJ, Davis L, et al. Work-related reactive airways dysfunction syndrome cases from surveillance in selected US states. J Occup Environ Med 2003; 45:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/25\">",
"      Tarlo SM, Broder I. Irritant-induced occupational asthma. Chest 1989; 96:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/26\">",
"      Wheeler K, McKelvey W, Thorpe L, et al. Asthma diagnosed after 11 September 2001 among rescue and recovery workers: findings from the World Trade Center Health Registry. Environ Health Perspect 2007; 115:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/27\">",
"      Banauch GI, Dhala A, Prezant DJ. Pulmonary disease in rescue workers at the World Trade Center site. Curr Opin Pulm Med 2005; 11:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/28\">",
"      Feldman DM, Baron SL, Bernard BP, et al. Symptoms, respirator use, and pulmonary function changes among New York City firefighters responding to the World Trade Center disaster. Chest 2004; 125:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/29\">",
"      Andersson E, Olin AC, Hagberg S, et al. Adult-onset asthma and wheeze among irritant-exposed bleachery workers. Am J Ind Med 2003; 43:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/30\">",
"      Karjalainen A, Martikainen R, Karjalainen J, et al. Excess incidence of asthma among Finnish cleaners employed in different industries. Eur Respir J 2002; 19:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/31\">",
"      Sherman CB, Barnhart S, Miller MF, et al. Firefighting acutely increases airway responsiveness. Am Rev Respir Dis 1989; 140:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/32\">",
"      Lemi&egrave;re C, Malo JL, Boulet LP, Boutet M. Reactive airways dysfunction syndrome induced by exposure to a mixture containing isocyanate: functional and histopathologic behaviour. Allergy 1996; 51:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/33\">",
"      Lemi&egrave;re C, Malo JL, Boutet M. Reactive airways dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Eur Respir J 1997; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/34\">",
"      Demnati R, Fraser R, Martin JG, et al. Effects of dexamethasone on functional and pathological changes in rat bronchi caused by high acute exposure to chlorine. Toxicol Sci 1998; 45:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/35\">",
"      Martin JG, Campbell HR, Iijima H, et al. Chlorine-induced injury to the airways in mice. Am J Respir Crit Care Med 2003; 168:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/36\">",
"      Takeda N, Maghni K, Daigle S, et al. Long-term pathologic consequences of acute irritant-induced asthma. J Allergy Clin Immunol 2009; 124:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/37\">",
"      Chang-Yeung M, Lam S, Kennedy SM, Frew AJ. Persistent asthma after repeated exposure to high concentrations of gases in pulpmills. Am J Respir Crit Care Med 1994; 149:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/38\">",
"      Gautrin D, Boulet LP, Boutet M, et al. Is reactive airways dysfunction syndrome a variant of occupational asthma? J Allergy Clin Immunol 1994; 93:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/39\">",
"      Cone JE, Wugofski L, Balmes JR, et al. Persistent respiratory health effects after a metam sodium pesticide spill. Chest 1994; 106:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/40\">",
"      Meggs WJ. RADS and RUDS--the toxic induction of asthma and rhinitis. J Toxicol Clin Toxicol 1994; 32:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/41\">",
"      White CW, Martin JG. Chlorine gas inhalation: human clinical evidence of toxicity and experience in animal models. Proc Am Thorac Soc 2010; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/42\">",
"      Malo JL, L'archev&ecirc;que J, Castellanos L, et al. Long-term outcomes of acute irritant-induced asthma. Am J Respir Crit Care Med 2009; 179:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/43\">",
"      Mauer MP, Cummings KR, Hoen R. Long-term respiratory symptoms in World Trade Center responders. Occup Med (Lond) 2010; 60:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/44\">",
"      Leroyer C, Malo JL, Girard D, et al. Chronic rhinitis in workers at risk of reactive airways dysfunction syndrome due to exposure to chlorine. Occup Environ Med 1999; 56:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/45\">",
"      Shusterman, D. Upper and lower airway sequelae of irritant inhalations. Clin Pulm Med 1999; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/46\">",
"      Courteau JP, Cushman R, Bouchard F, et al. Survey of construction workers repeatedly exposed to chlorine over a three to six month period in a pulpmill: I. Exposure and symptomatology. Occup Environ Med 1994; 51:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/47\">",
"      Vandenplas O, Fievez P, Delwiche JP, et al. Persistent asthma following accidental exposure to formaldehyde. Allergy 2004; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/48\">",
"      Charan NB, Lakshminarayan S, Myers GC, Smith DD. Effects of accidental chlorine inhalation on pulmonary function. West J Med 1985; 143:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/49\">",
"      de la Hoz RE. Occupational lower airway disease in relation to World Trade Center inhalation exposure. Curr Opin Allergy Clin Immunol 2011; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/50\">",
"      Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to \"sensitisation\" to isocyanates? Thorax 1998; 53:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/51\">",
"      Mendelson DS, Roggeveen M, Levin SM, et al. Air trapping detected on end-expiratory high-resolution computed tomography in symptomatic World Trade Center rescue and recovery workers. J Occup Environ Med 2007; 49:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/52\">",
"      Zock JP, Kogevinas M, Sunyer J, et al. Asthma characteristics in cleaning workers, workers in other risk jobs and office workers. Eur Respir J 2002; 20:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/53\">",
"      Perkner JJ, Fennelly KP, Balkissoon R, et al. Irritant-associated vocal cord dysfunction. J Occup Environ Med 1998; 40:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/54\">",
"      Quirce S. Eosinophilic bronchitis in the workplace. Curr Opin Allergy Clin Immunol 2004; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/55\">",
"      Tanaka H, Saikai T, Sugawara H, et al. Workplace-related chronic cough on a mushroom farm. Chest 2002; 122:1080.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 08, 2011).",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Full text is available online at: file://www.ginasthma.com (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/58\">",
"      Malo JL, Cartier A, Boulet LP, et al. Bronchial hyperresponsiveness can improve while spirometry plateaus two to three years after repeated exposure to chlorine causing respiratory symptoms. Am J Respir Crit Care Med 1994; 150:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/59\">",
"      Jones RN, Hughes JM, Glindmeyer H, Weill H. Lung function after acute chlorine exposure. Am Rev Respir Dis 1986; 134:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/60\">",
"      Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997; 112:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/61\">",
"      Aldrich TK, Gustave J, Hall CB, et al. Lung function in rescue workers at the World Trade Center after 7 years. N Engl J Med 2010; 362:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/28/8650/abstract/62\">",
"      Skloot GS, Schechter CB, Herbert R, et al. Longitudinal assessment of spirometry in the World Trade Center medical monitoring program. Chest 2009; 135:492.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 536 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8650=[""].join("\n");
var outline_f8_28_8650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31975798\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31976583\">",
"      CAUSES AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4798536\">",
"      PATHOLOGIC CORRELATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4797885\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4798684\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4798305\">",
"      Skin and immunologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4797893\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4798231\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4798224\">",
"      - Nonspecific bronchoprovocation challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4798276\">",
"      - Specific bronchoprovocation challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4798648\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361579\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18301455\">",
"      Acute presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18301462\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92154380\">",
"      Acute management of RADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92154406\">",
"      Management of chronic RADS or IrIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4798774\">",
"      EXPOSURE AVOIDANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31975798\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/536|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/62/26600\" title=\"algorithm 1\">",
"      Emergency Rx severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/536|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31949\" title=\"figure 1\">",
"      Severity restrictive dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/26/16814\" title=\"figure 2\">",
"      Severity obstructive dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 3\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/57/12187\" title=\"table 1\">",
"      Criteria associated with RADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/4/34893\" title=\"table 2A\">",
"      Agents responsible for RADS-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/32/32269\" title=\"table 2B\">",
"      Agents responsible for RADS-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/63/34811\" title=\"table 3\">",
"      Lesions after exposure to RADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/17/18715\" title=\"table 4\">",
"      Occupational asthma vs RADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/14/40171\" title=\"table 5\">",
"      Relevant info from RADS subject",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/61/24539\" title=\"table 6\">",
"      Contraindications to bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/29/7645\" title=\"table 7\">",
"      Medications and bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33693\" title=\"table 8\">",
"      Severe asthma exacerbation in adults rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 9\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 10\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/12/204\" title=\"table 11\">",
"      Usual doses oral gc asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14489?source=related_link\">",
"      Occupational asthma: Management, prognosis, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_28_8651="Other effects of high salt";
var content_f8_28_8651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Other associations with high salt intake independent of blood pressure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperfiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced effect of calcium channel blockers and ACE inhibitors on proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased calcium excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomach cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8651=[""].join("\n");
var outline_f8_28_8651=null;
var title_f8_28_8652="Major causes of DIC";
var content_f8_28_8652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Events that initiate DIC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Septicemia - Gram negative and Gram positive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Crush injury or complicated surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe head injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cancer procoagulant (Trousseau's syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute leukemia, especially promyelocytic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Complications of pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Amniotic fluid embolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Abruptio placentae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HELLP syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Eclampsia and severe preeclampsia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Dead fetus syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Septic abortion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amphetamine overdose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Giant hemangioma (Kasabach-Merritt syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal aortic aneurysm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peritoneovenous shunt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute hemolytic transfusion reaction (ABO incompatibility)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paroxysmal nocturnal hemoglobinuria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Snake and viper venoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Liver disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Fulminant hepatic failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reperfusion after liver transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heat stroke",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Burns",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Purpura fulminans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Events that complicate and propagate DIC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shock",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complement pathway activation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8652=[""].join("\n");
var outline_f8_28_8652=null;
var title_f8_28_8653="Theophylline poisoning - Rapid overview";
var content_f8_28_8653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Theophylline poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ingestion of sustained release oral preparations is most common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical findings: vomiting, hypokalemia, hyperglycemia, metabolic acidosis, seizures, sinus tachycardia and other tachyarrhythmias (SVT, VT), hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acutely poisoned patients are at high risk for seizures and arrhythmias if theophylline level &ge;80 to 100 micrograms/mL (448 to 560 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronically poisoned patients may be relatively asymptomatic at presentation and are at high risk for seizures and arrhythmias if age &le;6 months or over 65 years of age and theophylline level &ge;30 to 40 micrograms/mL (168 to 224 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        All symptomatic patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emergent serum theophylline level (in patients with an acute overdose, repeat every two hours until peak level occurs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum electrolytes, calcium, and glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Supportive care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vomiting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High dose ondansetron (0.15 mg/kg, maximum dose 8 to 12 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Seizures:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        First line: benzodiazepines (eg, lorazepam 0.05 to 0.1 mg/kg maximum 4 mg per dose) repeat once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Second line: phenobarbital (20 mg/kg loading dose maximum 1000 mg load), midazolam infusion, or propofol infusion depending on individual patient status. Avoid fosphenytoin or phenytoin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Arrhythmias:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Treat according to ACLS or PALS guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hypotension:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        First line: IV isotonic saline or Ringer's lactate (20 mL/kg, maximum 1 L), up to 60 mL/kg (3 L) and treatment of arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Second line: phenylephrine (IV bolus dose 5 to 20 mcg/kg per dose, maximum initial dose: 0.5 mg) or, in patients without asthma or COPD, propranolol (IV dose 0.01 to 0.1 mg/kg per dose, maximum initial dose 1 mg to 3 mg)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer activated charcoal 1 g/kg up to 50 grams followed by repeated doses (0.5 to 1 g/kg every 2 to 4 hours with cathartic [eg, sorbitol] no more than every third dose) for any significant ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perform high-efficiency hemodialysis in patients with high risk for life-threatening toxicity",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACLS: advanced cardiac life support; COPD: chronic obstructive pulmonary disease; IV: intravenous; PALS: pediatric advanced life support; SVT: supraventricular tachycardia; VT: ventricular tachycardia.",
"     <br/>",
"     * Administer propranolol slowly and initiated at the lower end of the dosing range in infants and the elderly.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     See the discussion of extracorporeal removal in the topic on Theophylline poisoning.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8653=[""].join("\n");
var outline_f8_28_8653=null;
var title_f8_28_8654="Pelvic pain in the pregnant adolescent female with no bleed";
var content_f8_28_8654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Evaluation of pelvic pain in the pregnant adolescent female without vaginal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound; SI: sacroiliac.",
"     <br>",
"      * FABERE sign consists of pain when the ipsilateral hip is placed in flexion, abduction, and external rotation, and the contralateral hip is placed in extension.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8654=[""].join("\n");
var outline_f8_28_8654=null;
var title_f8_28_8655="Cobblestoning buccal mucosa";
var content_f8_28_8655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cobblestone appearance of the buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the buccal mucosa in patients with Crohn disease may cause it to appear cobblestoned.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_28_8655=[""].join("\n");
var outline_f8_28_8655=null;
